[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "DUX4, a homeobox-containing gene present in a tandem array, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominant autosomal disease. New findings about DUX4 have raised as many fundamental questions about the molecular pathology of this unique disease as they have answered. This review discusses recent studies addressing the question of whether there is extensive FSHD-related transcription dysregulation in adult-derived myoblasts and myotubes, the precursors for muscle repair. Two models for the role of DUX4 in FSHD are presented. One involves transient pathogenic expression of DUX4 in many cells in the muscle lineage before the myoblast stage resulting in a persistent, disease-related transcription profile ('Majority Rules'), which might be enhanced by subsequent oscillatory expression of DUX4. The other model emphasizes the toxic effects of inappropriate expression of DUX4 in only an extremely small percentage of FSHD myoblasts or myotube nuclei ('Minority Rules'). The currently favored Minority Rules model is not supported by recent studies of transcription dysregulation in FSHD myoblasts and myotubes. It also presents other difficulties, for example, explaining the expression of full-length DUX4 transcripts in FSHD fibroblasts. The Majority Rules model is the simpler explanation of findings about FSHD-associated gene expression and the DUX4-encoded homeodomain-type protein.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "6a92b3312fe9468e9d709a8e59c9fadc", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[64, 64], [160, 160], [91, 91], [188, 188], [20, 20], [212, 212], [226, 226]], "char_spans": [[387, 390], [950, 953], [538, 541], [1115, 1118], [117, 120], [1255, 1258], [1343, 1346]]}]}], "context_tokens": [["DUX4", 0], [",", 4], ["a", 6], ["homeobox", 8], ["-", 16], ["containing", 17], ["gene", 28], ["present", 33], ["in", 41], ["a", 44], ["tandem", 46], ["array", 53], [",", 58], ["is", 60], ["implicated", 63], ["in", 74], ["facioscapulohumeral", 77], ["muscular", 97], ["dystrophy", 106], ["(", 116], ["FSHD", 117], [")", 121], [",", 122], ["a", 124], ["dominant", 126], ["autosomal", 135], ["disease", 145], [".", 152], ["New", 154], ["findings", 158], ["about", 167], ["DUX4", 173], ["have", 178], ["raised", 183], ["as", 190], ["many", 193], ["fundamental", 198], ["questions", 210], ["about", 220], ["the", 226], ["molecular", 230], ["pathology", 240], ["of", 250], ["this", 253], ["unique", 258], ["disease", 265], ["as", 273], ["they", 276], ["have", 281], ["answered", 286], [".", 294], ["This", 296], ["review", 301], ["discusses", 308], ["recent", 318], ["studies", 325], ["addressing", 333], ["the", 344], ["question", 348], ["of", 357], ["whether", 360], ["there", 368], ["is", 374], ["extensive", 377], ["FSHD", 387], ["-", 391], ["related", 392], ["transcription", 400], ["dysregulation", 414], ["in", 428], ["adult", 431], ["-", 436], ["derived", 437], ["myoblasts", 445], ["and", 455], ["myotubes", 459], [",", 467], ["the", 469], ["precursors", 473], ["for", 484], ["muscle", 488], ["repair", 495], [".", 501], ["Two", 503], ["models", 507], ["for", 514], ["the", 518], ["role", 522], ["of", 527], ["DUX4", 530], ["in", 535], ["FSHD", 538], ["are", 543], ["presented", 547], [".", 556], ["One", 558], ["involves", 562], ["transient", 571], ["pathogenic", 581], ["expression", 592], ["of", 603], ["DUX4", 606], ["in", 611], ["many", 614], ["cells", 619], ["in", 625], ["the", 628], ["muscle", 632], ["lineage", 639], ["before", 647], ["the", 654], ["myoblast", 658], ["stage", 667], ["resulting", 673], ["in", 683], ["a", 686], ["persistent", 688], [",", 698], ["disease", 700], ["-", 707], ["related", 708], ["transcription", 716], ["profile", 730], ["(", 738], ["'", 739], ["Majority", 740], ["Rules", 749], ["'", 754], [")", 755], [",", 756], ["which", 758], ["might", 764], ["be", 770], ["enhanced", 773], ["by", 782], ["subsequent", 785], ["oscillatory", 796], ["expression", 808], ["of", 819], ["DUX4", 822], [".", 826], ["The", 828], ["other", 832], ["model", 838], ["emphasizes", 844], ["the", 855], ["toxic", 859], ["effects", 865], ["of", 873], ["inappropriate", 876], ["expression", 890], ["of", 901], ["DUX4", 904], ["in", 909], ["only", 912], ["an", 917], ["extremely", 920], ["small", 930], ["percentage", 936], ["of", 947], ["FSHD", 950], ["myoblasts", 955], ["or", 965], ["myotube", 968], ["nuclei", 976], ["(", 983], ["'", 984], ["Minority", 985], ["Rules", 994], ["'", 999], [")", 1000], [".", 1001], ["The", 1003], ["currently", 1007], ["favored", 1017], ["Minority", 1025], ["Rules", 1034], ["model", 1040], ["is", 1046], ["not", 1049], ["supported", 1053], ["by", 1063], ["recent", 1066], ["studies", 1073], ["of", 1081], ["transcription", 1084], ["dysregulation", 1098], ["in", 1112], ["FSHD", 1115], ["myoblasts", 1120], ["and", 1130], ["myotubes", 1134], [".", 1142], ["It", 1144], ["also", 1147], ["presents", 1152], ["other", 1161], ["difficulties", 1167], [",", 1179], ["for", 1181], ["example", 1185], [",", 1192], ["explaining", 1194], ["the", 1205], ["expression", 1209], ["of", 1220], ["full", 1223], ["-", 1227], ["length", 1228], ["DUX4", 1235], ["transcripts", 1240], ["in", 1252], ["FSHD", 1255], ["fibroblasts", 1260], [".", 1271], ["The", 1273], ["Majority", 1277], ["Rules", 1286], ["model", 1292], ["is", 1298], ["the", 1301], ["simpler", 1305], ["explanation", 1313], ["of", 1325], ["findings", 1328], ["about", 1337], ["FSHD", 1343], ["-", 1347], ["associated", 1348], ["gene", 1359], ["expression", 1364], ["and", 1375], ["the", 1379], ["DUX4-encoded", 1383], ["homeodomain", 1396], ["-", 1407], ["type", 1408], ["protein", 1413], [".", 1420]]}
{"context": "Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin. Clinical symptomatology such as fatigability, cold intolerance, failure to concentrate and poor effort intolerance is often attributed to anemia or uremia. That iron deficiency, per se, can cause these symptoms is poorly recognized. Clinical and animal studies that support the benefits of iron supplementation, independent of increasing hemoglobin, such as those on immune function, physical performance, thermoregulation, cognition, and restless leg syndrome and aluminum absorption is the subject of this narrative review.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "9a096b481413444ea01bcdaa55383924", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [55, 55], [78, 78]], "char_spans": [[0, 3], [360, 363], [489, 492]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["anemia", 16], ["is", 23], ["common", 26], ["in", 33], ["people", 36], ["with", 43], ["chronic", 48], ["kidney", 56], ["disease", 63], ["(", 71], ["CKD", 72], [")", 75], ["and", 77], ["its", 81], ["importance", 85], ["in", 96], ["supporting", 99], ["erythropoiesis", 110], ["is", 125], ["unquestioned", 128], ["especially", 141], ["in", 152], ["those", 155], ["patients", 161], ["treated", 170], ["with", 178], ["erythropoietin", 183], [".", 197], ["Clinical", 199], ["symptomatology", 208], ["such", 223], ["as", 228], ["fatigability", 231], [",", 243], ["cold", 245], ["intolerance", 250], [",", 261], ["failure", 263], ["to", 271], ["concentrate", 274], ["and", 286], ["poor", 290], ["effort", 295], ["intolerance", 302], ["is", 314], ["often", 317], ["attributed", 323], ["to", 334], ["anemia", 337], ["or", 344], ["uremia", 347], [".", 353], ["That", 355], ["iron", 360], ["deficiency", 365], [",", 375], ["per", 377], ["se", 381], [",", 383], ["can", 385], ["cause", 389], ["these", 395], ["symptoms", 401], ["is", 410], ["poorly", 413], ["recognized", 420], [".", 430], ["Clinical", 432], ["and", 441], ["animal", 445], ["studies", 452], ["that", 460], ["support", 465], ["the", 473], ["benefits", 477], ["of", 486], ["iron", 489], ["supplementation", 494], [",", 509], ["independent", 511], ["of", 523], ["increasing", 526], ["hemoglobin", 537], [",", 547], ["such", 549], ["as", 554], ["those", 557], ["on", 563], ["immune", 566], ["function", 573], [",", 581], ["physical", 583], ["performance", 592], [",", 603], ["thermoregulation", 605], [",", 621], ["cognition", 623], [",", 632], ["and", 634], ["restless", 638], ["leg", 647], ["syndrome", 651], ["and", 660], ["aluminum", 664], ["absorption", 673], ["is", 684], ["the", 687], ["subject", 691], ["of", 699], ["this", 702], ["narrative", 707], ["review", 717], [".", 723]]}
{"context": "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission. Both drugs had a favorable therapeutic index. A 24-h treatment with 1,000 nM UC-781 or 100 nM TMC120-R147681 prevented cell-free HIV infection, whereas 10-fold-higher concentrations blocked cell-associated HIV.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c3236d984bae4fe9a702753a63371250", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[74, 74], [17, 17], [62, 62]], "char_spans": [[479, 481], [142, 144], [402, 404]]}]}], "context_tokens": [["The", 0], ["nonnucleoside", 4], ["reverse", 18], ["transcriptase", 26], ["inhibitors", 40], ["UC-781", 51], ["and", 58], ["TMC120-R147681", 62], ["(", 77], ["Dapivirine", 78], [")", 88], ["effectively", 90], ["prevented", 102], ["human", 112], ["immunodeficiency", 118], ["virus", 135], ["(", 141], ["HIV", 142], [")", 145], ["infection", 147], ["in", 157], ["cocultures", 160], ["of", 171], ["monocyte", 174], ["-", 182], ["derived", 183], ["dendritic", 191], ["cells", 201], ["and", 207], ["T", 211], ["cells", 213], [",", 218], ["representing", 220], ["primary", 233], ["targets", 241], ["in", 249], ["sexual", 252], ["transmission", 259], [".", 271], ["Both", 273], ["drugs", 278], ["had", 284], ["a", 288], ["favorable", 290], ["therapeutic", 300], ["index", 312], [".", 317], ["A", 319], ["24-h", 321], ["treatment", 326], ["with", 336], ["1,000", 341], ["nM", 347], ["UC-781", 350], ["or", 357], ["100", 360], ["nM", 364], ["TMC120-R147681", 367], ["prevented", 382], ["cell", 392], ["-", 396], ["free", 397], ["HIV", 402], ["infection", 406], [",", 415], ["whereas", 417], ["10-fold", 425], ["-", 432], ["higher", 433], ["concentrations", 440], ["blocked", 455], ["cell", 463], ["-", 467], ["associated", 468], ["HIV", 479], [".", 482]]}
{"context": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates. Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design. Population estimates and correlations were obtained for PTSD, generalized anxiety and depression. The reliability, factor structure, and convergent validity of the DTS-S were assessed. Cross-validation was employed to confirm the results of the factor analyses. Using the cut-offs adopted by the scale's author, 136 (13.4 percent) of the inmates are likely to have current PTSD and 117 (11.6 percent) reach the cut-off for sub-threshold PTSD. Confirmatory factor analysis generated two factors explaining 53 percent of the variance. High reliabilities were obtained for the total scale (\u03b1=0.95) and for the frequency and severity scales (\u03b1=0.90 and 0.91). Significantly higher DTS-S scores were found for females (t=2.26, p<0.025), for inmates diagnosed with depression or anxiety (t=2.02, p<0.05), and those reporting suicide attempts (t=4.47, p<0.0001). Findings support that the DTS-S is a reliable and valid measure to assess PTSD symptoms in Latino inmate populations and to identify individuals at risk for the disorder that require confirmatory diagnosis and clinical interventions.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b6a2b5c8312645a99ca848d823503319", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[34, 38]], "char_spans": [[178, 207]]}, {"text": "PTSD", "token_spans": [[160, 160], [144, 144], [40, 40], [254, 254], [81, 81]], "char_spans": [[844, 847], [780, 783], [210, 213], [1337, 1340], [463, 466]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["paper", 20], ["is", 26], ["to", 29], ["assess", 32], ["the", 39], ["reliability", 43], ["and", 55], ["validity", 59], ["of", 68], ["the", 71], ["Spanish", 75], ["version", 83], ["of", 91], ["the", 94], ["Davidson", 98], ["trauma", 107], ["scale", 114], ["(", 120], ["DTS", 121], ["-", 124], ["S", 125], [")", 126], ["and", 128], ["to", 132], ["determine", 135], ["the", 145], ["prevalence", 149], ["and", 160], ["correlates", 164], ["of", 175], ["post", 178], ["-", 182], ["traumatic", 183], ["stress", 193], ["disorder", 200], ["(", 209], ["PTSD", 210], [")", 214], ["symptoms", 216], ["in", 225], ["a", 228], ["non", 230], ["-", 233], ["clinical", 234], ["random", 243], ["sample", 250], ["of", 257], ["prison", 260], ["inmates", 267], [".", 274], ["Probabilistic", 276], ["samples", 290], ["of", 298], ["1,179", 301], ["inmates", 307], ["from", 315], ["26", 320], ["penal", 323], ["institutions", 329], ["in", 342], ["Puerto", 345], ["Rico", 352], ["were", 357], ["selected", 362], ["using", 371], ["a", 377], ["multistage", 379], ["sampling", 390], ["design", 399], [".", 405], ["Population", 407], ["estimates", 418], ["and", 428], ["correlations", 432], ["were", 445], ["obtained", 450], ["for", 459], ["PTSD", 463], [",", 467], ["generalized", 469], ["anxiety", 481], ["and", 489], ["depression", 493], [".", 503], ["The", 505], ["reliability", 509], [",", 520], ["factor", 522], ["structure", 529], [",", 538], ["and", 540], ["convergent", 544], ["validity", 555], ["of", 564], ["the", 567], ["DTS", 571], ["-", 574], ["S", 575], ["were", 577], ["assessed", 582], [".", 590], ["Cross", 592], ["-", 597], ["validation", 598], ["was", 609], ["employed", 613], ["to", 622], ["confirm", 625], ["the", 633], ["results", 637], ["of", 645], ["the", 648], ["factor", 652], ["analyses", 659], [".", 667], ["Using", 669], ["the", 675], ["cut", 679], ["-", 682], ["offs", 683], ["adopted", 688], ["by", 696], ["the", 699], ["scale", 703], ["'s", 708], ["author", 711], [",", 717], ["136", 719], ["(", 723], ["13.4", 724], ["percent", 729], [")", 736], ["of", 738], ["the", 741], ["inmates", 745], ["are", 753], ["likely", 757], ["to", 764], ["have", 767], ["current", 772], ["PTSD", 780], ["and", 785], ["117", 789], ["(", 793], ["11.6", 794], ["percent", 799], [")", 806], ["reach", 808], ["the", 814], ["cut", 818], ["-", 821], ["off", 822], ["for", 826], ["sub", 830], ["-", 833], ["threshold", 834], ["PTSD", 844], [".", 848], ["Confirmatory", 850], ["factor", 863], ["analysis", 870], ["generated", 879], ["two", 889], ["factors", 893], ["explaining", 901], ["53", 912], ["percent", 915], ["of", 923], ["the", 926], ["variance", 930], [".", 938], ["High", 940], ["reliabilities", 945], ["were", 959], ["obtained", 964], ["for", 973], ["the", 977], ["total", 981], ["scale", 987], ["(", 993], ["\u03b1=0.95", 994], [")", 1000], ["and", 1002], ["for", 1006], ["the", 1010], ["frequency", 1014], ["and", 1024], ["severity", 1028], ["scales", 1037], ["(", 1044], ["\u03b1=0.90", 1045], ["and", 1052], ["0.91", 1056], [")", 1060], [".", 1061], ["Significantly", 1063], ["higher", 1077], ["DTS", 1084], ["-", 1087], ["S", 1088], ["scores", 1090], ["were", 1097], ["found", 1102], ["for", 1108], ["females", 1112], ["(", 1120], ["t=2.26", 1121], [",", 1127], ["p<0.025", 1129], [")", 1136], [",", 1137], ["for", 1139], ["inmates", 1143], ["diagnosed", 1151], ["with", 1161], ["depression", 1166], ["or", 1177], ["anxiety", 1180], ["(", 1188], ["t=2.02", 1189], [",", 1195], ["p<0.05", 1197], [")", 1203], [",", 1204], ["and", 1206], ["those", 1210], ["reporting", 1216], ["suicide", 1226], ["attempts", 1234], ["(", 1243], ["t=4.47", 1244], [",", 1250], ["p<0.0001", 1252], [")", 1260], [".", 1261], ["Findings", 1263], ["support", 1272], ["that", 1280], ["the", 1285], ["DTS", 1289], ["-", 1292], ["S", 1293], ["is", 1295], ["a", 1298], ["reliable", 1300], ["and", 1309], ["valid", 1313], ["measure", 1319], ["to", 1327], ["assess", 1330], ["PTSD", 1337], ["symptoms", 1342], ["in", 1351], ["Latino", 1354], ["inmate", 1361], ["populations", 1368], ["and", 1380], ["to", 1384], ["identify", 1387], ["individuals", 1396], ["at", 1408], ["risk", 1411], ["for", 1416], ["the", 1420], ["disorder", 1424], ["that", 1433], ["require", 1438], ["confirmatory", 1446], ["diagnosis", 1459], ["and", 1469], ["clinical", 1473], ["interventions", 1482], [".", 1495]]}
{"context": "To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery. Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method. Genital distribution of NPs and their ability to modify the PK of dapivirine up to 24 h was assessed after vaginal instillation in a female mouse model. Also, the safety of NPs upon daily administration for 14 days was assessed by histological analysis and chemokine/cytokine content in vaginal lavages. PEO-PCL NPs (180-200 nm) were rapidly eliminated after administration but able to distribute throughout the vagina and lower uterus, and capable of tackling mucus and penetrate the epithelial lining. Nanocarriers modified the PK of dapivirine, with higher drug levels being recovered from vaginal lavages and vaginal/lower uterine tissues as compared to a drug suspension. Systemic drug exposure was reduced when NPs were used. Also, NPs were shown safe upon administration for 14 days. Dapivirine-loaded PEO-PCL NPs were able to provide likely favorable genital drug levels, thus attesting the potential value of using this vaginal drug delivery nanosystem in the context of HIV prophylaxis.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "1e55c4f1758248f58dd8977c35ab8ead", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[27, 27], [234, 234]], "char_spans": [[149, 151], [1328, 1330]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["potential", 14], ["of", 24], ["polymeric", 27], ["nanoparticles", 37], ["(", 51], ["NPs", 52], [")", 55], ["to", 57], ["affect", 60], ["the", 67], ["genital", 71], ["distribution", 79], ["and", 92], ["local", 96], ["and", 102], ["systemic", 106], ["pharmacokinetics", 115], ["(", 132], ["PK", 133], [")", 135], ["of", 137], ["the", 140], ["anti", 144], ["-", 148], ["HIV", 149], ["microbicide", 153], ["drug", 165], ["candidate", 170], ["dapivirine", 180], ["after", 191], ["vaginal", 197], ["delivery", 205], [".", 213], ["Dapivirine", 215], ["-", 225], ["loaded", 226], [",", 232], ["poly(ethylene", 234], ["oxide)-coated", 248], ["poly(epsilon", 262], ["-", 274], ["caprolactone", 275], [")", 287], ["(", 289], ["PEO", 290], ["-", 293], ["PCL", 294], [")", 297], ["NPs", 299], ["were", 303], ["prepared", 308], ["by", 317], ["a", 320], ["nanoprecipitation", 322], ["method", 340], [".", 346], ["Genital", 348], ["distribution", 356], ["of", 369], ["NPs", 372], ["and", 376], ["their", 380], ["ability", 386], ["to", 394], ["modify", 397], ["the", 404], ["PK", 408], ["of", 411], ["dapivirine", 414], ["up", 425], ["to", 428], ["24", 431], ["h", 434], ["was", 436], ["assessed", 440], ["after", 449], ["vaginal", 455], ["instillation", 463], ["in", 476], ["a", 479], ["female", 481], ["mouse", 488], ["model", 494], [".", 499], ["Also", 501], [",", 505], ["the", 507], ["safety", 511], ["of", 518], ["NPs", 521], ["upon", 525], ["daily", 530], ["administration", 536], ["for", 551], ["14", 555], ["days", 558], ["was", 563], ["assessed", 567], ["by", 576], ["histological", 579], ["analysis", 592], ["and", 601], ["chemokine", 605], ["/", 614], ["cytokine", 615], ["content", 624], ["in", 632], ["vaginal", 635], ["lavages", 643], [".", 650], ["PEO", 652], ["-", 655], ["PCL", 656], ["NPs", 660], ["(", 664], ["180", 665], ["-", 668], ["200", 669], ["nm", 673], [")", 675], ["were", 677], ["rapidly", 682], ["eliminated", 690], ["after", 701], ["administration", 707], ["but", 722], ["able", 726], ["to", 731], ["distribute", 734], ["throughout", 745], ["the", 756], ["vagina", 760], ["and", 767], ["lower", 771], ["uterus", 777], [",", 783], ["and", 785], ["capable", 789], ["of", 797], ["tackling", 800], ["mucus", 809], ["and", 815], ["penetrate", 819], ["the", 829], ["epithelial", 833], ["lining", 844], [".", 850], ["Nanocarriers", 852], ["modified", 865], ["the", 874], ["PK", 878], ["of", 881], ["dapivirine", 884], [",", 894], ["with", 896], ["higher", 901], ["drug", 908], ["levels", 913], ["being", 920], ["recovered", 926], ["from", 936], ["vaginal", 941], ["lavages", 949], ["and", 957], ["vaginal", 961], ["/", 968], ["lower", 969], ["uterine", 975], ["tissues", 983], ["as", 991], ["compared", 994], ["to", 1003], ["a", 1006], ["drug", 1008], ["suspension", 1013], [".", 1023], ["Systemic", 1025], ["drug", 1034], ["exposure", 1039], ["was", 1048], ["reduced", 1052], ["when", 1060], ["NPs", 1065], ["were", 1069], ["used", 1074], [".", 1078], ["Also", 1080], [",", 1084], ["NPs", 1086], ["were", 1090], ["shown", 1095], ["safe", 1101], ["upon", 1106], ["administration", 1111], ["for", 1126], ["14", 1130], ["days", 1133], [".", 1137], ["Dapivirine", 1139], ["-", 1149], ["loaded", 1150], ["PEO", 1157], ["-", 1160], ["PCL", 1161], ["NPs", 1165], ["were", 1169], ["able", 1174], ["to", 1179], ["provide", 1182], ["likely", 1190], ["favorable", 1197], ["genital", 1207], ["drug", 1215], ["levels", 1220], [",", 1226], ["thus", 1228], ["attesting", 1233], ["the", 1243], ["potential", 1247], ["value", 1257], ["of", 1263], ["using", 1266], ["this", 1272], ["vaginal", 1277], ["drug", 1285], ["delivery", 1290], ["nanosystem", 1299], ["in", 1310], ["the", 1313], ["context", 1317], ["of", 1325], ["HIV", 1328], ["prophylaxis", 1332], [".", 1343]]}
{"context": "By using monoclonal antibodies raised against isolated clam centrosomes, we have identified a novel 135-kD centrosomal protein (Cep135), present in a wide range of organisms. Cep135 is located at the centrosome throughout the cell cycle, and localization is independent of the microtubule network. It distributes throughout the centrosomal area in association with the electron-dense material surrounding centrioles. Sequence analysis of cDNA isolated from CHO cells predicted a protein of 1,145-amino acid residues with extensive alpha-helical domains. Expression of a series of deletion constructs revealed the presence of three independent centrosome-targeting domains. Overexpression of Cep135 resulted in the accumulation of unique whorl-like particles in both the centrosome and the cytoplasm. Although their size, shape, and number varied according to the level of protein expression, these whorls were composed of parallel dense lines arranged in a 6-nm space. Altered levels of Cep135 by protein overexpression and/or suppression of endogenous Cep135 by RNA interference caused disorganization of interphase and mitotic spindle microtubules. Thus, Cep135 may play an important role in the centrosomal function of organizing microtubules in mammalian cells.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "531659cef16e4f2d9ad354129f13c0c8", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[123, 123], [35, 35], [102, 102]], "char_spans": [[770, 779], [200, 209], [643, 652]]}]}], "context_tokens": [["By", 0], ["using", 3], ["monoclonal", 9], ["antibodies", 20], ["raised", 31], ["against", 38], ["isolated", 46], ["clam", 55], ["centrosomes", 60], [",", 71], ["we", 73], ["have", 76], ["identified", 81], ["a", 92], ["novel", 94], ["135-kD", 100], ["centrosomal", 107], ["protein", 119], ["(", 127], ["Cep135", 128], [")", 134], [",", 135], ["present", 137], ["in", 145], ["a", 148], ["wide", 150], ["range", 155], ["of", 161], ["organisms", 164], [".", 173], ["Cep135", 175], ["is", 182], ["located", 185], ["at", 193], ["the", 196], ["centrosome", 200], ["throughout", 211], ["the", 222], ["cell", 226], ["cycle", 231], [",", 236], ["and", 238], ["localization", 242], ["is", 255], ["independent", 258], ["of", 270], ["the", 273], ["microtubule", 277], ["network", 289], [".", 296], ["It", 298], ["distributes", 301], ["throughout", 313], ["the", 324], ["centrosomal", 328], ["area", 340], ["in", 345], ["association", 348], ["with", 360], ["the", 365], ["electron", 369], ["-", 377], ["dense", 378], ["material", 384], ["surrounding", 393], ["centrioles", 405], [".", 415], ["Sequence", 417], ["analysis", 426], ["of", 435], ["cDNA", 438], ["isolated", 443], ["from", 452], ["CHO", 457], ["cells", 461], ["predicted", 467], ["a", 477], ["protein", 479], ["of", 487], ["1,145-amino", 490], ["acid", 502], ["residues", 507], ["with", 516], ["extensive", 521], ["alpha", 531], ["-", 536], ["helical", 537], ["domains", 545], [".", 552], ["Expression", 554], ["of", 565], ["a", 568], ["series", 570], ["of", 577], ["deletion", 580], ["constructs", 589], ["revealed", 600], ["the", 609], ["presence", 613], ["of", 622], ["three", 625], ["independent", 631], ["centrosome", 643], ["-", 653], ["targeting", 654], ["domains", 664], [".", 671], ["Overexpression", 673], ["of", 688], ["Cep135", 691], ["resulted", 698], ["in", 707], ["the", 710], ["accumulation", 714], ["of", 727], ["unique", 730], ["whorl", 737], ["-", 742], ["like", 743], ["particles", 748], ["in", 758], ["both", 761], ["the", 766], ["centrosome", 770], ["and", 781], ["the", 785], ["cytoplasm", 789], [".", 798], ["Although", 800], ["their", 809], ["size", 815], [",", 819], ["shape", 821], [",", 826], ["and", 828], ["number", 832], ["varied", 839], ["according", 846], ["to", 856], ["the", 859], ["level", 863], ["of", 869], ["protein", 872], ["expression", 880], [",", 890], ["these", 892], ["whorls", 898], ["were", 905], ["composed", 910], ["of", 919], ["parallel", 922], ["dense", 931], ["lines", 937], ["arranged", 943], ["in", 952], ["a", 955], ["6-nm", 957], ["space", 962], [".", 967], ["Altered", 969], ["levels", 977], ["of", 984], ["Cep135", 987], ["by", 994], ["protein", 997], ["overexpression", 1005], ["and/or", 1020], ["suppression", 1027], ["of", 1039], ["endogenous", 1042], ["Cep135", 1053], ["by", 1060], ["RNA", 1063], ["interference", 1067], ["caused", 1080], ["disorganization", 1087], ["of", 1103], ["interphase", 1106], ["and", 1117], ["mitotic", 1121], ["spindle", 1129], ["microtubules", 1137], [".", 1149], ["Thus", 1151], [",", 1155], ["Cep135", 1157], ["may", 1164], ["play", 1168], ["an", 1173], ["important", 1176], ["role", 1186], ["in", 1191], ["the", 1194], ["centrosomal", 1198], ["function", 1210], ["of", 1219], ["organizing", 1222], ["microtubules", 1233], ["in", 1246], ["mammalian", 1249], ["cells", 1259], [".", 1264]]}
{"context": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor. In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21). We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004). Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clinically relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003). Because most mutation-positive tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime (\"never smokers\"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers. Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001). Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concentrations of drug. Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "29f2855a4f1e49cabf0d468c74465cb7", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[12, 19]], "char_spans": [[60, 103]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["(", 41], ["TK", 42], [")", 44], ["domain", 46], ["of", 53], ["the", 56], ["epidermal", 60], ["growth", 70], ["factor", 77], ["receptor", 84], ["(", 93], ["EGFR", 94], [")", 98], ["gene", 100], ["are", 105], ["reportedly", 109], ["associated", 120], ["with", 131], ["sensitivity", 136], ["of", 148], ["lung", 151], ["cancers", 156], ["to", 164], ["gefitinib", 167], ["(", 177], ["Iressa", 178], [")", 184], [",", 185], ["kinase", 187], ["inhibitor", 194], [".", 203], ["In", 205], ["-", 207], ["frame", 208], ["deletions", 214], ["occur", 224], ["in", 230], ["exon", 233], ["19", 238], [",", 240], ["whereas", 242], ["point", 250], ["mutations", 256], ["occur", 266], ["frequently", 272], ["in", 283], ["codon", 286], ["858", 292], ["(", 296], ["exon", 297], ["21", 302], [")", 304], [".", 305], ["We", 307], ["found", 310], ["from", 316], ["sequencing", 321], ["the", 332], ["EGFR", 336], ["TK", 341], ["domain", 344], ["that", 351], ["7", 356], ["of", 358], ["10", 361], ["gefitinib", 364], ["-", 373], ["sensitive", 374], ["tumors", 384], ["had", 391], ["similar", 395], ["types", 403], ["of", 409], ["alterations", 412], [";", 423], ["no", 425], ["mutations", 428], ["were", 438], ["found", 443], ["in", 449], ["eight", 452], ["gefitinib", 458], ["-", 467], ["refractory", 468], ["tumors", 479], ["(", 486], ["P", 487], ["=", 489], ["0.004", 491], [")", 496], [".", 497], ["Five", 499], ["of", 504], ["seven", 507], ["tumors", 513], ["sensitive", 520], ["to", 530], ["erlotinib", 533], ["(", 543], ["Tarceva", 544], [")", 551], [",", 552], ["a", 554], ["related", 556], ["kinase", 564], ["inhibitor", 571], ["for", 581], ["which", 585], ["the", 591], ["clinically", 595], ["relevant", 606], ["target", 615], ["is", 622], ["undocumented", 625], [",", 637], ["had", 639], ["analogous", 643], ["somatic", 653], ["mutations", 661], [",", 670], ["as", 672], ["opposed", 675], ["to", 683], ["none", 686], ["of", 691], ["10", 694], ["erlotinib", 697], ["-", 706], ["refractory", 707], ["tumors", 718], ["(", 725], ["P", 726], ["=", 728], ["0.003", 730], [")", 735], [".", 736], ["Because", 738], ["most", 746], ["mutation", 751], ["-", 759], ["positive", 760], ["tumors", 769], ["were", 776], ["adenocarcinomas", 781], ["from", 797], ["patients", 802], ["who", 811], ["smoked", 815], ["<", 822], ["100", 823], ["cigarettes", 827], ["in", 838], ["a", 841], ["lifetime", 843], ["(", 852], ["\"", 853], ["never", 854], ["smokers", 860], ["\"", 867], [")", 868], [",", 869], ["we", 871], ["screened", 874], ["EGFR", 883], ["exons", 888], ["2", 894], ["-", 895], ["28", 896], ["in", 899], ["15", 902], ["adenocarcinomas", 905], ["resected", 921], ["from", 930], ["untreated", 935], ["never", 945], ["smokers", 951], [".", 958], ["Seven", 960], ["tumors", 966], ["had", 973], ["TK", 977], ["domain", 980], ["mutations", 987], [",", 996], ["in", 998], ["contrast", 1001], ["to", 1010], ["4", 1013], ["of", 1015], ["81", 1018], ["non", 1021], ["-", 1024], ["small", 1025], ["cell", 1031], ["lung", 1036], ["cancers", 1041], ["resected", 1049], ["from", 1058], ["untreated", 1063], ["former", 1073], ["or", 1080], ["current", 1083], ["smokers", 1091], ["(", 1099], ["P", 1100], ["=", 1102], ["0.0001", 1104], [")", 1110], [".", 1111], ["Immunoblotting", 1113], ["of", 1128], ["lysates", 1131], ["from", 1139], ["cells", 1144], ["transiently", 1150], ["transfected", 1162], ["with", 1174], ["various", 1179], ["EGFR", 1187], ["constructs", 1192], ["demonstrated", 1203], ["that", 1216], [",", 1220], ["compared", 1222], ["to", 1231], ["wild", 1234], ["-", 1238], ["type", 1239], ["protein", 1244], [",", 1251], ["an", 1253], ["exon", 1256], ["19", 1261], ["deletion", 1264], ["mutant", 1273], ["induced", 1280], ["diminished", 1288], ["levels", 1299], ["of", 1306], ["phosphotyrosine", 1309], [",", 1324], ["whereas", 1326], ["the", 1334], ["phosphorylation", 1338], ["at", 1354], ["tyrosine", 1357], ["1092", 1366], ["of", 1371], ["an", 1374], ["exon", 1377], ["21", 1382], ["point", 1385], ["mutant", 1391], ["was", 1398], ["inhibited", 1402], ["at", 1412], ["10-fold", 1415], ["lower", 1423], ["concentrations", 1429], ["of", 1444], ["drug", 1447], [".", 1451], ["Collectively", 1453], [",", 1465], ["these", 1467], ["data", 1473], ["show", 1478], ["that", 1483], ["adenocarcinomas", 1488], ["from", 1504], ["never", 1509], ["smokers", 1515], ["comprise", 1523], ["a", 1532], ["distinct", 1534], ["subset", 1543], ["of", 1550], ["lung", 1553], ["cancers", 1558], [",", 1565], ["frequently", 1567], ["containing", 1578], ["mutations", 1589], ["within", 1599], ["the", 1606], ["TK", 1610], ["domain", 1613], ["of", 1620], ["EGFR", 1623], ["that", 1628], ["are", 1633], ["associated", 1637], ["with", 1648], ["gefitinib", 1653], ["and", 1663], ["erlotinib", 1667], ["sensitivity", 1677], [".", 1688]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by hypoproliferative anemia, associated physical malformations and a predisposition to cancer. DBA has been associated with mutations and deletions in the large and small ribosomal protein genes, and genetic aberrations have been detected in \u223c50-60% of patients. In this study, nine Korean DBA patients were screened for mutations in eight known DBA genes (RPS19, RPS24, RPS17, RPS10, RPS26, RPL35A, RPL5 and RPL11) using the direct sequencing method. Mutations in RPS19, RPS26 and RPS17 were detected in four, two and one patient, respectively. Among the mutations detected in RPS19, two mutations were novel (c.26T>A, c.357-2A>G). For the mutation-negative cases, array-CGH analysis was performed to identify copy-number variations, and no deletions involving the known DBA gene regions were identified. The relative mRNA expression of RPS19 estimated using real-time quantitative PCR analysis revealed two- to fourfold reductions in RPS19 mRNA expression in three patients with RPS19 mutations, and p53 protein expression analysis by immunohistochemistry showed variable but significant nuclear staining in the DBA patients. In conclusion, heterozygous mutations in the known DBA genes RPS19, RPS26 and RPS17 were detected in seven out of nine Korean DBA patients. Among these patients, RPS19 was the most frequently mutated gene. In addition, decreased RPS19 mRNA expression and p53 overexpression were observed in the Korean DBA patients, which supports the hypothesis that haploinsufficiency and p53 hyperactivation represent a central pathway underlying the pathogenesis of DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "7b98e597897f4b24bd7030143bae73d8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [229, 229], [74, 74], [218, 218], [294, 294], [28, 28], [244, 244], [167, 167], [274, 274], [65, 65]], "char_spans": [[25, 27], [1268, 1270], [435, 437], [1203, 1205], [1670, 1672], [184, 186], [1343, 1345], [861, 863], [1519, 1521], [379, 381]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["hypoproliferative", 92], ["anemia", 110], [",", 116], ["associated", 118], ["physical", 129], ["malformations", 138], ["and", 152], ["a", 156], ["predisposition", 158], ["to", 173], ["cancer", 176], [".", 182], ["DBA", 184], ["has", 188], ["been", 192], ["associated", 197], ["with", 208], ["mutations", 213], ["and", 223], ["deletions", 227], ["in", 237], ["the", 240], ["large", 244], ["and", 250], ["small", 254], ["ribosomal", 260], ["protein", 270], ["genes", 278], [",", 283], ["and", 285], ["genetic", 289], ["aberrations", 297], ["have", 309], ["been", 314], ["detected", 319], ["in", 328], ["\u223c50", 331], ["-", 334], ["60", 335], ["%", 337], ["of", 339], ["patients", 342], [".", 350], ["In", 352], ["this", 355], ["study", 360], [",", 365], ["nine", 367], ["Korean", 372], ["DBA", 379], ["patients", 383], ["were", 392], ["screened", 397], ["for", 406], ["mutations", 410], ["in", 420], ["eight", 423], ["known", 429], ["DBA", 435], ["genes", 439], ["(", 445], ["RPS19", 446], [",", 451], ["RPS24", 453], [",", 458], ["RPS17", 460], [",", 465], ["RPS10", 467], [",", 472], ["RPS26", 474], [",", 479], ["RPL35A", 481], [",", 487], ["RPL5", 489], ["and", 494], ["RPL11", 498], [")", 503], ["using", 505], ["the", 511], ["direct", 515], ["sequencing", 522], ["method", 533], [".", 539], ["Mutations", 541], ["in", 551], ["RPS19", 554], [",", 559], ["RPS26", 561], ["and", 567], ["RPS17", 571], ["were", 577], ["detected", 582], ["in", 591], ["four", 594], [",", 598], ["two", 600], ["and", 604], ["one", 608], ["patient", 612], [",", 619], ["respectively", 621], [".", 633], ["Among", 635], ["the", 641], ["mutations", 645], ["detected", 655], ["in", 664], ["RPS19", 667], [",", 672], ["two", 674], ["mutations", 678], ["were", 688], ["novel", 693], ["(", 699], ["c.26T", 700], [">", 705], ["A", 706], [",", 707], ["c.357", 709], ["-", 714], ["2A", 715], [">", 717], ["G", 718], [")", 719], [".", 720], ["For", 722], ["the", 726], ["mutation", 730], ["-", 738], ["negative", 739], ["cases", 748], [",", 753], ["array", 755], ["-", 760], ["CGH", 761], ["analysis", 765], ["was", 774], ["performed", 778], ["to", 788], ["identify", 791], ["copy", 800], ["-", 804], ["number", 805], ["variations", 812], [",", 822], ["and", 824], ["no", 828], ["deletions", 831], ["involving", 841], ["the", 851], ["known", 855], ["DBA", 861], ["gene", 865], ["regions", 870], ["were", 878], ["identified", 883], [".", 893], ["The", 895], ["relative", 899], ["mRNA", 908], ["expression", 913], ["of", 924], ["RPS19", 927], ["estimated", 933], ["using", 943], ["real", 949], ["-", 953], ["time", 954], ["quantitative", 959], ["PCR", 972], ["analysis", 976], ["revealed", 985], ["two-", 994], ["to", 999], ["fourfold", 1002], ["reductions", 1011], ["in", 1022], ["RPS19", 1025], ["mRNA", 1031], ["expression", 1036], ["in", 1047], ["three", 1050], ["patients", 1056], ["with", 1065], ["RPS19", 1070], ["mutations", 1076], [",", 1085], ["and", 1087], ["p53", 1091], ["protein", 1095], ["expression", 1103], ["analysis", 1114], ["by", 1123], ["immunohistochemistry", 1126], ["showed", 1147], ["variable", 1154], ["but", 1163], ["significant", 1167], ["nuclear", 1179], ["staining", 1187], ["in", 1196], ["the", 1199], ["DBA", 1203], ["patients", 1207], [".", 1215], ["In", 1217], ["conclusion", 1220], [",", 1230], ["heterozygous", 1232], ["mutations", 1245], ["in", 1255], ["the", 1258], ["known", 1262], ["DBA", 1268], ["genes", 1272], ["RPS19", 1278], [",", 1283], ["RPS26", 1285], ["and", 1291], ["RPS17", 1295], ["were", 1301], ["detected", 1306], ["in", 1315], ["seven", 1318], ["out", 1324], ["of", 1328], ["nine", 1331], ["Korean", 1336], ["DBA", 1343], ["patients", 1347], [".", 1355], ["Among", 1357], ["these", 1363], ["patients", 1369], [",", 1377], ["RPS19", 1379], ["was", 1385], ["the", 1389], ["most", 1393], ["frequently", 1398], ["mutated", 1409], ["gene", 1417], [".", 1421], ["In", 1423], ["addition", 1426], [",", 1434], ["decreased", 1436], ["RPS19", 1446], ["mRNA", 1452], ["expression", 1457], ["and", 1468], ["p53", 1472], ["overexpression", 1476], ["were", 1491], ["observed", 1496], ["in", 1505], ["the", 1508], ["Korean", 1512], ["DBA", 1519], ["patients", 1523], [",", 1531], ["which", 1533], ["supports", 1539], ["the", 1548], ["hypothesis", 1552], ["that", 1563], ["haploinsufficiency", 1568], ["and", 1587], ["p53", 1591], ["hyperactivation", 1595], ["represent", 1611], ["a", 1621], ["central", 1623], ["pathway", 1631], ["underlying", 1639], ["the", 1650], ["pathogenesis", 1654], ["of", 1667], ["DBA", 1670], [".", 1673]]}
{"context": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome. Men, however, are more likely than women to die from extra-articular complications of rheumatoid disease. This chapter discusses the outcome and mortality studies that substantiate these conclusions and then examines the possible mechanisms that may account for them, including the HLA system, seropositivity, compliance, response to therapy and pain threshold. In particular, sex and sex hormones emerge as independent risk factors in rheumatoid disease. The epidemiological evidence points towards a peak age of onset of RA at the time of the menopause in women and towards later in life in men. Premenopausal women may fare better than postmenopausal women with RA. The possible protective effects of the oral contraceptive pill and the dramatic amelioration with pregnancy are well documented. In vivo and in vitro studies have demonstrated that sex hormones interfere with a number of the putative processes involved in the pathogenesis of RA, including immunoregulation, interaction with inflammatory mediators and the cytokine system, and direct effects on cartilage itself. All these observations point towards the importance of gonadal hormones. However, trials on the potential therapeutic use of sex hormones in RA are limited and, as yet, disappointing. Further work is necessary to determine whether the roles of sex hormones are as central protagonists or just supporting cast in the complex arena of rheumatoid disease.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "dd55ff8b09a7433aa467295dae5b0c62", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[16, 16], [127, 127], [137, 137], [40, 40], [143, 143]], "char_spans": [[86, 90], [721, 725], [775, 779], [198, 202], [817, 821]]}]}], "context_tokens": [["Disease", 0], ["patterns", 8], ["in", 17], ["RA", 20], ["vary", 23], ["between", 28], ["the", 36], ["sexes", 40], [";", 45], ["the", 47], ["condition", 51], ["is", 61], ["more", 64], ["commonly", 69], ["seen", 78], ["in", 83], ["women", 86], [",", 91], ["who", 93], ["exhibit", 97], ["a", 105], ["more", 107], ["aggressive", 112], ["disease", 123], ["and", 131], ["a", 135], ["poorer", 137], ["long", 144], ["-", 148], ["term", 149], ["outcome", 154], [".", 161], ["Men", 163], [",", 166], ["however", 168], [",", 175], ["are", 177], ["more", 181], ["likely", 186], ["than", 193], ["women", 198], ["to", 204], ["die", 207], ["from", 211], ["extra", 216], ["-", 221], ["articular", 222], ["complications", 232], ["of", 246], ["rheumatoid", 249], ["disease", 260], [".", 267], ["This", 269], ["chapter", 274], ["discusses", 282], ["the", 292], ["outcome", 296], ["and", 304], ["mortality", 308], ["studies", 318], ["that", 326], ["substantiate", 331], ["these", 344], ["conclusions", 350], ["and", 362], ["then", 366], ["examines", 371], ["the", 380], ["possible", 384], ["mechanisms", 393], ["that", 404], ["may", 409], ["account", 413], ["for", 421], ["them", 425], [",", 429], ["including", 431], ["the", 441], ["HLA", 445], ["system", 449], [",", 455], ["seropositivity", 457], [",", 471], ["compliance", 473], [",", 483], ["response", 485], ["to", 494], ["therapy", 497], ["and", 505], ["pain", 509], ["threshold", 514], [".", 523], ["In", 525], ["particular", 528], [",", 538], ["sex", 540], ["and", 544], ["sex", 548], ["hormones", 552], ["emerge", 561], ["as", 568], ["independent", 571], ["risk", 583], ["factors", 588], ["in", 596], ["rheumatoid", 599], ["disease", 610], [".", 617], ["The", 619], ["epidemiological", 623], ["evidence", 639], ["points", 648], ["towards", 655], ["a", 663], ["peak", 665], ["age", 670], ["of", 674], ["onset", 677], ["of", 683], ["RA", 686], ["at", 689], ["the", 692], ["time", 696], ["of", 701], ["the", 704], ["menopause", 708], ["in", 718], ["women", 721], ["and", 727], ["towards", 731], ["later", 739], ["in", 745], ["life", 748], ["in", 753], ["men", 756], [".", 759], ["Premenopausal", 761], ["women", 775], ["may", 781], ["fare", 785], ["better", 790], ["than", 797], ["postmenopausal", 802], ["women", 817], ["with", 823], ["RA", 828], [".", 830], ["The", 832], ["possible", 836], ["protective", 845], ["effects", 856], ["of", 864], ["the", 867], ["oral", 871], ["contraceptive", 876], ["pill", 890], ["and", 895], ["the", 899], ["dramatic", 903], ["amelioration", 912], ["with", 925], ["pregnancy", 930], ["are", 940], ["well", 944], ["documented", 949], [".", 959], ["In", 961], ["vivo", 964], ["and", 969], ["in", 973], ["vitro", 976], ["studies", 982], ["have", 990], ["demonstrated", 995], ["that", 1008], ["sex", 1013], ["hormones", 1017], ["interfere", 1026], ["with", 1036], ["a", 1041], ["number", 1043], ["of", 1050], ["the", 1053], ["putative", 1057], ["processes", 1066], ["involved", 1076], ["in", 1085], ["the", 1088], ["pathogenesis", 1092], ["of", 1105], ["RA", 1108], [",", 1110], ["including", 1112], ["immunoregulation", 1122], [",", 1138], ["interaction", 1140], ["with", 1152], ["inflammatory", 1157], ["mediators", 1170], ["and", 1180], ["the", 1184], ["cytokine", 1188], ["system", 1197], [",", 1203], ["and", 1205], ["direct", 1209], ["effects", 1216], ["on", 1224], ["cartilage", 1227], ["itself", 1237], [".", 1243], ["All", 1245], ["these", 1249], ["observations", 1255], ["point", 1268], ["towards", 1274], ["the", 1282], ["importance", 1286], ["of", 1297], ["gonadal", 1300], ["hormones", 1308], [".", 1316], ["However", 1318], [",", 1325], ["trials", 1327], ["on", 1334], ["the", 1337], ["potential", 1341], ["therapeutic", 1351], ["use", 1363], ["of", 1367], ["sex", 1370], ["hormones", 1374], ["in", 1383], ["RA", 1386], ["are", 1389], ["limited", 1393], ["and", 1401], [",", 1404], ["as", 1406], ["yet", 1409], [",", 1412], ["disappointing", 1414], [".", 1427], ["Further", 1429], ["work", 1437], ["is", 1442], ["necessary", 1445], ["to", 1455], ["determine", 1458], ["whether", 1468], ["the", 1476], ["roles", 1480], ["of", 1486], ["sex", 1489], ["hormones", 1493], ["are", 1502], ["as", 1506], ["central", 1509], ["protagonists", 1517], ["or", 1530], ["just", 1533], ["supporting", 1538], ["cast", 1549], ["in", 1554], ["the", 1557], ["complex", 1561], ["arena", 1569], ["of", 1575], ["rheumatoid", 1578], ["disease", 1589], [".", 1596]]}
{"context": "There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials. The present paper describes, for a pivotal phase III efficacy of the RTS, S/AS01 malaria vaccine, the methods of the statistical analysis and the rationale for their selection. The methods used to estimate efficacy of the primary course of vaccination, and of a booster dose, in preventing clinical episodes of uncomplicated and severe malaria, and to determine the duration of protection, are described. The interpretation of various measures of efficacy in terms of the potential public health impact of the vaccine is discussed. The methodology selected to analyse the clinical trial must be scientifically sound, acceptable to regulatory authorities and meaningful to those responsible for malaria control and public health policy.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "565e79886a2d468ab49544a0c8e4d2c9", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[146, 146], [89, 89], [46, 46], [14, 14]], "char_spans": [[878, 884], [520, 526], [265, 271], [95, 101]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["much", 15], ["debate", 20], ["about", 27], ["the", 33], ["appropriate", 37], ["statistical", 49], ["methodology", 61], ["for", 73], ["the", 77], ["evaluation", 81], ["of", 92], ["malaria", 95], ["field", 103], ["studies", 109], ["and", 117], ["the", 121], ["challenges", 125], ["in", 136], ["interpreting", 139], ["data", 152], ["arising", 157], ["from", 165], ["these", 170], ["trials", 176], [".", 182], ["The", 184], ["present", 188], ["paper", 196], ["describes", 202], [",", 211], ["for", 213], ["a", 217], ["pivotal", 219], ["phase", 227], ["III", 233], ["efficacy", 237], ["of", 246], ["the", 249], ["RTS", 253], [",", 256], ["S", 258], ["/", 259], ["AS01", 260], ["malaria", 265], ["vaccine", 273], [",", 280], ["the", 282], ["methods", 286], ["of", 294], ["the", 297], ["statistical", 301], ["analysis", 313], ["and", 322], ["the", 326], ["rationale", 330], ["for", 340], ["their", 344], ["selection", 350], [".", 359], ["The", 361], ["methods", 365], ["used", 373], ["to", 378], ["estimate", 381], ["efficacy", 390], ["of", 399], ["the", 402], ["primary", 406], ["course", 414], ["of", 421], ["vaccination", 424], [",", 435], ["and", 437], ["of", 441], ["a", 444], ["booster", 446], ["dose", 454], [",", 458], ["in", 460], ["preventing", 463], ["clinical", 474], ["episodes", 483], ["of", 492], ["uncomplicated", 495], ["and", 509], ["severe", 513], ["malaria", 520], [",", 527], ["and", 529], ["to", 533], ["determine", 536], ["the", 546], ["duration", 550], ["of", 559], ["protection", 562], [",", 572], ["are", 574], ["described", 578], [".", 587], ["The", 589], ["interpretation", 593], ["of", 608], ["various", 611], ["measures", 619], ["of", 628], ["efficacy", 631], ["in", 640], ["terms", 643], ["of", 649], ["the", 652], ["potential", 656], ["public", 666], ["health", 673], ["impact", 680], ["of", 687], ["the", 690], ["vaccine", 694], ["is", 702], ["discussed", 705], [".", 714], ["The", 716], ["methodology", 720], ["selected", 732], ["to", 741], ["analyse", 744], ["the", 752], ["clinical", 756], ["trial", 765], ["must", 771], ["be", 776], ["scientifically", 779], ["sound", 794], [",", 799], ["acceptable", 801], ["to", 812], ["regulatory", 815], ["authorities", 826], ["and", 838], ["meaningful", 842], ["to", 853], ["those", 856], ["responsible", 862], ["for", 874], ["malaria", 878], ["control", 886], ["and", 894], ["public", 898], ["health", 905], ["policy", 912], [".", 918]]}
{"context": "Stroke recognition tools have been shown to improve diagnostic accuracy in adults. Development of a similar tool in children is needed to reduce lag time to diagnosis. A critical first step is to determine whether adult stoke scales can be applied in childhood stroke.Our objective was to assess the applicability of adult stroke scales in childhood arterial ischemic stroke (AIS) METHODS: Children aged 1 month to < 18 years with radiologically confirmed acute AIS who presented to a tertiary emergency department (ED) (2003 to 2008) were identified retrospectively. Signs, symptoms, risk factors and initial management were extracted. Two adult stroke recognition tools; ROSIER (Recognition of Stroke in the Emergency Room) and FAST (Face Arm Speech Test) scales were applied retrospectively to all patients to determine test sensitivity. 47 children with AIS were identified. 34 had anterior, 12 had posterior and 1 child had anterior and posterior circulation infarcts. Median age was 9 years and 51% were male. Median time from symptom onset to ED presentation was 21 hours but one third of children presented within 6 hours. The most common presenting stroke symptoms were arm (63%), face (62%), leg weakness (57%), speech disturbance (46%) and headache (46%). The most common signs were arm (61%), face (70%) or leg weakness (57%) and dysarthria (34%). 36 (78%) of children had at least one positive variable on FAST and 38 (81%) had a positive score of \u22651 on the ROSIER scale. Positive scores were less likely in children with posterior circulation stroke. The presenting features of pediatric stroke appear similar to adult strokes. Two adult stroke recognition tools have fair to good sensitivity in radiologically confirmed childhood AIS but require further development and modification. Specificity of the tools also needs to be determined in a prospective cohort of children with stroke and non-stroke brain attacks.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "1c541feb2e3d42fa943dbf7eb67303a8", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[0, 0], [208, 208], [45, 45], [315, 315], [122, 122], [331, 331], [371, 371], [62, 62], [56, 56], [322, 322], [114, 114], [367, 367]], "char_spans": [[0, 5], [1158, 1163], [261, 266], [1557, 1562], [696, 701], [1652, 1657], [1908, 1913], [368, 373], [323, 328], [1602, 1607], [647, 652], [1893, 1898]]}]}], "context_tokens": [["Stroke", 0], ["recognition", 7], ["tools", 19], ["have", 25], ["been", 30], ["shown", 35], ["to", 41], ["improve", 44], ["diagnostic", 52], ["accuracy", 63], ["in", 72], ["adults", 75], [".", 81], ["Development", 83], ["of", 95], ["a", 98], ["similar", 100], ["tool", 108], ["in", 113], ["children", 116], ["is", 125], ["needed", 128], ["to", 135], ["reduce", 138], ["lag", 145], ["time", 149], ["to", 154], ["diagnosis", 157], [".", 166], ["A", 168], ["critical", 170], ["first", 179], ["step", 185], ["is", 190], ["to", 193], ["determine", 196], ["whether", 206], ["adult", 214], ["stoke", 220], ["scales", 226], ["can", 233], ["be", 237], ["applied", 240], ["in", 248], ["childhood", 251], ["stroke", 261], [".", 267], ["Our", 268], ["objective", 272], ["was", 282], ["to", 286], ["assess", 289], ["the", 296], ["applicability", 300], ["of", 314], ["adult", 317], ["stroke", 323], ["scales", 330], ["in", 337], ["childhood", 340], ["arterial", 350], ["ischemic", 359], ["stroke", 368], ["(", 375], ["AIS", 376], [")", 379], ["METHODS", 381], [":", 388], ["Children", 390], ["aged", 399], ["1", 404], ["month", 406], ["to", 412], ["<", 415], ["18", 417], ["years", 420], ["with", 426], ["radiologically", 431], ["confirmed", 446], ["acute", 456], ["AIS", 462], ["who", 466], ["presented", 470], ["to", 480], ["a", 483], ["tertiary", 485], ["emergency", 494], ["department", 504], ["(", 515], ["ED", 516], [")", 518], ["(", 520], ["2003", 521], ["to", 526], ["2008", 529], [")", 533], ["were", 535], ["identified", 540], ["retrospectively", 551], [".", 566], ["Signs", 568], [",", 573], ["symptoms", 575], [",", 583], ["risk", 585], ["factors", 590], ["and", 598], ["initial", 602], ["management", 610], ["were", 621], ["extracted", 626], [".", 635], ["Two", 637], ["adult", 641], ["stroke", 647], ["recognition", 654], ["tools", 666], [";", 671], ["ROSIER", 673], ["(", 680], ["Recognition", 681], ["of", 693], ["Stroke", 696], ["in", 703], ["the", 706], ["Emergency", 710], ["Room", 720], [")", 724], ["and", 726], ["FAST", 730], ["(", 735], ["Face", 736], ["Arm", 741], ["Speech", 745], ["Test", 752], [")", 756], ["scales", 758], ["were", 765], ["applied", 770], ["retrospectively", 778], ["to", 794], ["all", 797], ["patients", 801], ["to", 810], ["determine", 813], ["test", 823], ["sensitivity", 828], [".", 839], ["47", 841], ["children", 844], ["with", 853], ["AIS", 858], ["were", 862], ["identified", 867], [".", 877], ["34", 879], ["had", 882], ["anterior", 886], [",", 894], ["12", 896], ["had", 899], ["posterior", 903], ["and", 913], ["1", 917], ["child", 919], ["had", 925], ["anterior", 929], ["and", 938], ["posterior", 942], ["circulation", 952], ["infarcts", 964], [".", 972], ["Median", 974], ["age", 981], ["was", 985], ["9", 989], ["years", 991], ["and", 997], ["51", 1001], ["%", 1003], ["were", 1005], ["male", 1010], [".", 1014], ["Median", 1016], ["time", 1023], ["from", 1028], ["symptom", 1033], ["onset", 1041], ["to", 1047], ["ED", 1050], ["presentation", 1053], ["was", 1066], ["21", 1070], ["hours", 1073], ["but", 1079], ["one", 1083], ["third", 1087], ["of", 1093], ["children", 1096], ["presented", 1105], ["within", 1115], ["6", 1122], ["hours", 1124], [".", 1129], ["The", 1131], ["most", 1135], ["common", 1140], ["presenting", 1147], ["stroke", 1158], ["symptoms", 1165], ["were", 1174], ["arm", 1179], ["(", 1183], ["63", 1184], ["%", 1186], [")", 1187], [",", 1188], ["face", 1190], ["(", 1195], ["62", 1196], ["%", 1198], [")", 1199], [",", 1200], ["leg", 1202], ["weakness", 1206], ["(", 1215], ["57", 1216], ["%", 1218], [")", 1219], [",", 1220], ["speech", 1222], ["disturbance", 1229], ["(", 1241], ["46", 1242], ["%", 1244], [")", 1245], ["and", 1247], ["headache", 1251], ["(", 1260], ["46", 1261], ["%", 1263], [")", 1264], [".", 1265], ["The", 1267], ["most", 1271], ["common", 1276], ["signs", 1283], ["were", 1289], ["arm", 1294], ["(", 1298], ["61", 1299], ["%", 1301], [")", 1302], [",", 1303], ["face", 1305], ["(", 1310], ["70", 1311], ["%", 1313], [")", 1314], ["or", 1316], ["leg", 1319], ["weakness", 1323], ["(", 1332], ["57", 1333], ["%", 1335], [")", 1336], ["and", 1338], ["dysarthria", 1342], ["(", 1353], ["34", 1354], ["%", 1356], [")", 1357], [".", 1358], ["36", 1360], ["(", 1363], ["78", 1364], ["%", 1366], [")", 1367], ["of", 1369], ["children", 1372], ["had", 1381], ["at", 1385], ["least", 1388], ["one", 1394], ["positive", 1398], ["variable", 1407], ["on", 1416], ["FAST", 1419], ["and", 1424], ["38", 1428], ["(", 1431], ["81", 1432], ["%", 1434], [")", 1435], ["had", 1437], ["a", 1441], ["positive", 1443], ["score", 1452], ["of", 1458], ["\u22651", 1461], ["on", 1464], ["the", 1467], ["ROSIER", 1471], ["scale", 1478], [".", 1483], ["Positive", 1485], ["scores", 1494], ["were", 1501], ["less", 1506], ["likely", 1511], ["in", 1518], ["children", 1521], ["with", 1530], ["posterior", 1535], ["circulation", 1545], ["stroke", 1557], [".", 1563], ["The", 1565], ["presenting", 1569], ["features", 1580], ["of", 1589], ["pediatric", 1592], ["stroke", 1602], ["appear", 1609], ["similar", 1616], ["to", 1624], ["adult", 1627], ["strokes", 1633], [".", 1640], ["Two", 1642], ["adult", 1646], ["stroke", 1652], ["recognition", 1659], ["tools", 1671], ["have", 1677], ["fair", 1682], ["to", 1687], ["good", 1690], ["sensitivity", 1695], ["in", 1707], ["radiologically", 1710], ["confirmed", 1725], ["childhood", 1735], ["AIS", 1745], ["but", 1749], ["require", 1753], ["further", 1761], ["development", 1769], ["and", 1781], ["modification", 1785], [".", 1797], ["Specificity", 1799], ["of", 1811], ["the", 1814], ["tools", 1818], ["also", 1824], ["needs", 1829], ["to", 1835], ["be", 1838], ["determined", 1841], ["in", 1852], ["a", 1855], ["prospective", 1857], ["cohort", 1869], ["of", 1876], ["children", 1879], ["with", 1888], ["stroke", 1893], ["and", 1900], ["non", 1904], ["-", 1907], ["stroke", 1908], ["brain", 1915], ["attacks", 1921], [".", 1928]]}
{"context": "The major protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein, but other proteins, in particular the microtubule-associated protein tau, have been implicated in the pathogenesis of LBs. Tau is the major structural component of neurofibrillary tangles (NFTs). Both direct immunochemical studies of partially purified LBs and indirect immunohistochemical studies have suggested that LBs may contain tau, but most of these studies were based upon a single tau antibody, and immunologic cross-reactivity was not completely excluded. To gain insight into the relation between tau and alpha-synuclein in LBs, double immunostaining was performed in Lewy body cases with a rabbit polyclonal antibody to alpha-synuclein and a panel of monoclonal antibodies to phospho- and nonphospho-tau epitopes (Alz50, CP9, CP13, PG5, TG3, PHFI) that spanned the length of the tau molecule. Tau-immunoreactive LBs were present in the medulla in 80% of the cases, irrespective of Braak stage. All tau antibodies recognized at least some LBs, arguing against nonspecific antibody cross-reactivity. In most lesions the tau immunostaining was present at the periphery of the LB. The phospho-tau antibody, TG3, detected more LBs than any of the other tau antibodies. The proportion of LBs with tau immunoreactivity was greatest in neurons vulnerable to NETs, such as those in the locus ceruleus and basal nucleus of Meynert, and least in neurons resistant to NFTs, such as the dorsal motor nucleus of the vagus in the medulla. The present results suggest that tau may coaggregate with alpha-synuclein in LBs, especially in neuronal populations vulnerable to both NFTs and LBs.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "dd51992abbdc4acdbe0da902d5a6786a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[306, 308], [138, 140], [118, 120], [27, 29]], "char_spans": [[1661, 1675], [799, 813], [683, 697], [150, 164]]}]}], "context_tokens": [["The", 0], ["major", 4], ["protein", 10], ["constituent", 18], ["of", 30], ["Lewy", 33], ["bodies", 38], ["(", 45], ["LBs", 46], [")", 49], [",", 50], ["the", 52], ["pathological", 56], ["hallmark", 69], ["of", 78], ["Parkinson", 81], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [",", 128], ["is", 130], ["considered", 133], ["to", 144], ["be", 147], ["alpha", 150], ["-", 155], ["synuclein", 156], [",", 165], ["but", 167], ["other", 171], ["proteins", 177], [",", 185], ["in", 187], ["particular", 190], ["the", 201], ["microtubule", 205], ["-", 216], ["associated", 217], ["protein", 228], ["tau", 236], [",", 239], ["have", 241], ["been", 246], ["implicated", 251], ["in", 262], ["the", 265], ["pathogenesis", 269], ["of", 282], ["LBs", 285], [".", 288], ["Tau", 290], ["is", 294], ["the", 297], ["major", 301], ["structural", 307], ["component", 318], ["of", 328], ["neurofibrillary", 331], ["tangles", 347], ["(", 355], ["NFTs", 356], [")", 360], [".", 361], ["Both", 363], ["direct", 368], ["immunochemical", 375], ["studies", 390], ["of", 398], ["partially", 401], ["purified", 411], ["LBs", 420], ["and", 424], ["indirect", 428], ["immunohistochemical", 437], ["studies", 457], ["have", 465], ["suggested", 470], ["that", 480], ["LBs", 485], ["may", 489], ["contain", 493], ["tau", 501], [",", 504], ["but", 506], ["most", 510], ["of", 515], ["these", 518], ["studies", 524], ["were", 532], ["based", 537], ["upon", 543], ["a", 548], ["single", 550], ["tau", 557], ["antibody", 561], [",", 569], ["and", 571], ["immunologic", 575], ["cross", 587], ["-", 592], ["reactivity", 593], ["was", 604], ["not", 608], ["completely", 612], ["excluded", 623], [".", 631], ["To", 633], ["gain", 636], ["insight", 641], ["into", 649], ["the", 654], ["relation", 658], ["between", 667], ["tau", 675], ["and", 679], ["alpha", 683], ["-", 688], ["synuclein", 689], ["in", 699], ["LBs", 702], [",", 705], ["double", 707], ["immunostaining", 714], ["was", 729], ["performed", 733], ["in", 743], ["Lewy", 746], ["body", 751], ["cases", 756], ["with", 762], ["a", 767], ["rabbit", 769], ["polyclonal", 776], ["antibody", 787], ["to", 796], ["alpha", 799], ["-", 804], ["synuclein", 805], ["and", 815], ["a", 819], ["panel", 821], ["of", 827], ["monoclonal", 830], ["antibodies", 841], ["to", 852], ["phospho-", 855], ["and", 864], ["nonphospho", 868], ["-", 878], ["tau", 879], ["epitopes", 883], ["(", 892], ["Alz50", 893], [",", 898], ["CP9", 900], [",", 903], ["CP13", 905], [",", 909], ["PG5", 911], [",", 914], ["TG3", 916], [",", 919], ["PHFI", 921], [")", 925], ["that", 927], ["spanned", 932], ["the", 940], ["length", 944], ["of", 951], ["the", 954], ["tau", 958], ["molecule", 962], [".", 970], ["Tau", 972], ["-", 975], ["immunoreactive", 976], ["LBs", 991], ["were", 995], ["present", 1000], ["in", 1008], ["the", 1011], ["medulla", 1015], ["in", 1023], ["80", 1026], ["%", 1028], ["of", 1030], ["the", 1033], ["cases", 1037], [",", 1042], ["irrespective", 1044], ["of", 1057], ["Braak", 1060], ["stage", 1066], [".", 1071], ["All", 1073], ["tau", 1077], ["antibodies", 1081], ["recognized", 1092], ["at", 1103], ["least", 1106], ["some", 1112], ["LBs", 1117], [",", 1120], ["arguing", 1122], ["against", 1130], ["nonspecific", 1138], ["antibody", 1150], ["cross", 1159], ["-", 1164], ["reactivity", 1165], [".", 1175], ["In", 1177], ["most", 1180], ["lesions", 1185], ["the", 1193], ["tau", 1197], ["immunostaining", 1201], ["was", 1216], ["present", 1220], ["at", 1228], ["the", 1231], ["periphery", 1235], ["of", 1245], ["the", 1248], ["LB", 1252], [".", 1254], ["The", 1256], ["phospho", 1260], ["-", 1267], ["tau", 1268], ["antibody", 1272], [",", 1280], ["TG3", 1282], [",", 1285], ["detected", 1287], ["more", 1296], ["LBs", 1301], ["than", 1305], ["any", 1310], ["of", 1314], ["the", 1317], ["other", 1321], ["tau", 1327], ["antibodies", 1331], [".", 1341], ["The", 1343], ["proportion", 1347], ["of", 1358], ["LBs", 1361], ["with", 1365], ["tau", 1370], ["immunoreactivity", 1374], ["was", 1391], ["greatest", 1395], ["in", 1404], ["neurons", 1407], ["vulnerable", 1415], ["to", 1426], ["NETs", 1429], [",", 1433], ["such", 1435], ["as", 1440], ["those", 1443], ["in", 1449], ["the", 1452], ["locus", 1456], ["ceruleus", 1462], ["and", 1471], ["basal", 1475], ["nucleus", 1481], ["of", 1489], ["Meynert", 1492], [",", 1499], ["and", 1501], ["least", 1505], ["in", 1511], ["neurons", 1514], ["resistant", 1522], ["to", 1532], ["NFTs", 1535], [",", 1539], ["such", 1541], ["as", 1546], ["the", 1549], ["dorsal", 1553], ["motor", 1560], ["nucleus", 1566], ["of", 1574], ["the", 1577], ["vagus", 1581], ["in", 1587], ["the", 1590], ["medulla", 1594], [".", 1601], ["The", 1603], ["present", 1607], ["results", 1615], ["suggest", 1623], ["that", 1631], ["tau", 1636], ["may", 1640], ["coaggregate", 1644], ["with", 1656], ["alpha", 1661], ["-", 1666], ["synuclein", 1667], ["in", 1677], ["LBs", 1680], [",", 1683], ["especially", 1685], ["in", 1696], ["neuronal", 1699], ["populations", 1708], ["vulnerable", 1720], ["to", 1731], ["both", 1734], ["NFTs", 1739], ["and", 1744], ["LBs", 1748], [".", 1751]]}
{"context": "We review the current evidence for medical and surgical treatments of spontaneous intracerebral hemorrhage (ICH). Therapy with hemostatic agents (e.g. factor VIIa and tranexamic acid) if started early after bleeding onset may reduce hematoma expansion, but their clinical effectiveness has not been shown. Rapid anticoagulation reversal with prothrombin concentrates (PCC) plus vitamin K is the first choice in vitamin K antagonist-related ICH. In ICH related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab. PCC are recommended for ICH related to FXa inhibitors, whereas specific reversal agents are not yet approved. While awaiting ongoing trials studying minimally invasive approaches or hemicraniectomy, the role of surgery in ICH remains to be defined. Therapies targeting downstream molecular cascades in order to prevent secondary neuronal damage are promising, but the complexity and multi-phased nature of ICH pathophysiology is challenging. Finally, in addition to blood pressure control, antithrombotic prevention after ICH has to consider the risk of recurrent bleeding as well as the risk of ischemic events. Treatment of acute ICH remains challenging, and many promising interventions for acute ICH await further evidence from trials.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d40ca4a4e2a1425fbe7308353258a879", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[78, 78]], "char_spans": [[463, 472]]}]}], "context_tokens": [["We", 0], ["review", 3], ["the", 10], ["current", 14], ["evidence", 22], ["for", 31], ["medical", 35], ["and", 43], ["surgical", 47], ["treatments", 56], ["of", 67], ["spontaneous", 70], ["intracerebral", 82], ["hemorrhage", 96], ["(", 107], ["ICH", 108], [")", 111], [".", 112], ["Therapy", 114], ["with", 122], ["hemostatic", 127], ["agents", 138], ["(", 145], ["e.g.", 146], ["factor", 151], ["VIIa", 158], ["and", 163], ["tranexamic", 167], ["acid", 178], [")", 182], ["if", 184], ["started", 187], ["early", 195], ["after", 201], ["bleeding", 207], ["onset", 216], ["may", 222], ["reduce", 226], ["hematoma", 233], ["expansion", 242], [",", 251], ["but", 253], ["their", 257], ["clinical", 263], ["effectiveness", 272], ["has", 286], ["not", 290], ["been", 294], ["shown", 299], [".", 304], ["Rapid", 306], ["anticoagulation", 312], ["reversal", 328], ["with", 337], ["prothrombin", 342], ["concentrates", 354], ["(", 367], ["PCC", 368], [")", 371], ["plus", 373], ["vitamin", 378], ["K", 386], ["is", 388], ["the", 391], ["first", 395], ["choice", 401], ["in", 408], ["vitamin", 411], ["K", 419], ["antagonist", 421], ["-", 431], ["related", 432], ["ICH", 440], [".", 443], ["In", 445], ["ICH", 448], ["related", 452], ["to", 460], ["dabigatran", 463], [",", 473], ["anticoagulation", 475], ["can", 491], ["be", 495], ["rapidly", 498], ["reversed", 506], ["with", 515], ["idarucizumab", 520], [".", 532], ["PCC", 534], ["are", 538], ["recommended", 542], ["for", 554], ["ICH", 558], ["related", 562], ["to", 570], ["FXa", 573], ["inhibitors", 577], [",", 587], ["whereas", 589], ["specific", 597], ["reversal", 606], ["agents", 615], ["are", 622], ["not", 626], ["yet", 630], ["approved", 634], [".", 642], ["While", 644], ["awaiting", 650], ["ongoing", 659], ["trials", 667], ["studying", 674], ["minimally", 683], ["invasive", 693], ["approaches", 702], ["or", 713], ["hemicraniectomy", 716], [",", 731], ["the", 733], ["role", 737], ["of", 742], ["surgery", 745], ["in", 753], ["ICH", 756], ["remains", 760], ["to", 768], ["be", 771], ["defined", 774], [".", 781], ["Therapies", 783], ["targeting", 793], ["downstream", 803], ["molecular", 814], ["cascades", 824], ["in", 833], ["order", 836], ["to", 842], ["prevent", 845], ["secondary", 853], ["neuronal", 863], ["damage", 872], ["are", 879], ["promising", 883], [",", 892], ["but", 894], ["the", 898], ["complexity", 902], ["and", 913], ["multi", 917], ["-", 922], ["phased", 923], ["nature", 930], ["of", 937], ["ICH", 940], ["pathophysiology", 944], ["is", 960], ["challenging", 963], [".", 974], ["Finally", 976], [",", 983], ["in", 985], ["addition", 988], ["to", 997], ["blood", 1000], ["pressure", 1006], ["control", 1015], [",", 1022], ["antithrombotic", 1024], ["prevention", 1039], ["after", 1050], ["ICH", 1056], ["has", 1060], ["to", 1064], ["consider", 1067], ["the", 1076], ["risk", 1080], ["of", 1085], ["recurrent", 1088], ["bleeding", 1098], ["as", 1107], ["well", 1110], ["as", 1115], ["the", 1118], ["risk", 1122], ["of", 1127], ["ischemic", 1130], ["events", 1139], [".", 1145], ["Treatment", 1147], ["of", 1157], ["acute", 1160], ["ICH", 1166], ["remains", 1170], ["challenging", 1178], [",", 1189], ["and", 1191], ["many", 1195], ["promising", 1200], ["interventions", 1210], ["for", 1224], ["acute", 1228], ["ICH", 1234], ["await", 1238], ["further", 1244], ["evidence", 1252], ["from", 1261], ["trials", 1266], [".", 1272]]}
{"context": "H2A.Z is a highly conserved variant of histone H2A with well-characterized roles in transcriptional regulation. We previously reported that H2A.Z and Mcd1, a subunit of the cohesin complex, regulate the establishment of transcriptional silencing at telomeres in Saccharomyces cerevisiae and that H2A.Z broadly dissociated from chromatin during the anaphase-to-telophase transition, coincident with the dissociation of Mcd1 from chromosomes and dissolution of cohesion. In this study, we show that depletion of H2A.Z causes precocious loss of sister chromatid cohesion in yeast without loss of Mcd1 from chromosomes. H2A.Z is deposited into chromatin by the SWR1 complex and is subject to acetylation of its four N-terminal tail lysine residues by the NuA4 and SAGA histone acetyltransferase complexes. We found that cells compromised for function of the SWR1 complex were defective in cohesion, as were cells expressing a form of H2A.Z not subject to acetylation. Finally, inactivation of H2A.Z in metaphase-blocked cells led immediately to cohesion defects, suggesting a direct role for H2A.Z in the maintenance of sister chromatid cohesion.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "4ef05543761e4948b74e9fa078a5e4bc", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[140, 140], [106, 106]], "char_spans": [[854, 857], [657, 660]]}]}], "context_tokens": [["H2A.Z", 0], ["is", 6], ["a", 9], ["highly", 11], ["conserved", 18], ["variant", 28], ["of", 36], ["histone", 39], ["H2A", 47], ["with", 51], ["well", 56], ["-", 60], ["characterized", 61], ["roles", 75], ["in", 81], ["transcriptional", 84], ["regulation", 100], [".", 110], ["We", 112], ["previously", 115], ["reported", 126], ["that", 135], ["H2A.Z", 140], ["and", 146], ["Mcd1", 150], [",", 154], ["a", 156], ["subunit", 158], ["of", 166], ["the", 169], ["cohesin", 173], ["complex", 181], [",", 188], ["regulate", 190], ["the", 199], ["establishment", 203], ["of", 217], ["transcriptional", 220], ["silencing", 236], ["at", 246], ["telomeres", 249], ["in", 259], ["Saccharomyces", 262], ["cerevisiae", 276], ["and", 287], ["that", 291], ["H2A.Z", 296], ["broadly", 302], ["dissociated", 310], ["from", 322], ["chromatin", 327], ["during", 337], ["the", 344], ["anaphase", 348], ["-", 356], ["to", 357], ["-", 359], ["telophase", 360], ["transition", 370], [",", 380], ["coincident", 382], ["with", 393], ["the", 398], ["dissociation", 402], ["of", 415], ["Mcd1", 418], ["from", 423], ["chromosomes", 428], ["and", 440], ["dissolution", 444], ["of", 456], ["cohesion", 459], [".", 467], ["In", 469], ["this", 472], ["study", 477], [",", 482], ["we", 484], ["show", 487], ["that", 492], ["depletion", 497], ["of", 507], ["H2A.Z", 510], ["causes", 516], ["precocious", 523], ["loss", 534], ["of", 539], ["sister", 542], ["chromatid", 549], ["cohesion", 559], ["in", 568], ["yeast", 571], ["without", 577], ["loss", 585], ["of", 590], ["Mcd1", 593], ["from", 598], ["chromosomes", 603], [".", 614], ["H2A.Z", 616], ["is", 622], ["deposited", 625], ["into", 635], ["chromatin", 640], ["by", 650], ["the", 653], ["SWR1", 657], ["complex", 662], ["and", 670], ["is", 674], ["subject", 677], ["to", 685], ["acetylation", 688], ["of", 700], ["its", 703], ["four", 707], ["N", 712], ["-", 713], ["terminal", 714], ["tail", 723], ["lysine", 728], ["residues", 735], ["by", 744], ["the", 747], ["NuA4", 751], ["and", 756], ["SAGA", 760], ["histone", 765], ["acetyltransferase", 773], ["complexes", 791], [".", 800], ["We", 802], ["found", 805], ["that", 811], ["cells", 816], ["compromised", 822], ["for", 834], ["function", 838], ["of", 847], ["the", 850], ["SWR1", 854], ["complex", 859], ["were", 867], ["defective", 872], ["in", 882], ["cohesion", 885], [",", 893], ["as", 895], ["were", 898], ["cells", 903], ["expressing", 909], ["a", 920], ["form", 922], ["of", 927], ["H2A.Z", 930], ["not", 936], ["subject", 940], ["to", 948], ["acetylation", 951], [".", 962], ["Finally", 964], [",", 971], ["inactivation", 973], ["of", 986], ["H2A.Z", 989], ["in", 995], ["metaphase", 998], ["-", 1007], ["blocked", 1008], ["cells", 1016], ["led", 1022], ["immediately", 1026], ["to", 1038], ["cohesion", 1041], ["defects", 1050], [",", 1057], ["suggesting", 1059], ["a", 1070], ["direct", 1072], ["role", 1079], ["for", 1084], ["H2A.Z", 1088], ["in", 1094], ["the", 1097], ["maintenance", 1101], ["of", 1113], ["sister", 1116], ["chromatid", 1123], ["cohesion", 1133], [".", 1141]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "2c9a3ae9437648e1834a87d46d29cd29", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "Mammalian selenium-containing proteins identified thus far contain selenium in the form of a selenocysteine residue encoded by UGA. These proteins lack common amino acid sequence motifs, but 3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECIS) element, that is necessary for decoding UGA as selenocysteine rather than a stop signal. We describe here a computer program, SECISearch, that identifies mammalian selenoprotein genes by recognizing SECIS elements on the basis of their primary and secondary structures and free energy requirements. When SECISearch was applied to search human dbEST, two new mammalian selenoproteins, designated SelT and SelR, were identified. We determined their cDNA sequences and expressed them in a monkey cell line as fusion proteins with a green fluorescent protein. Incorporation of selenium into new proteins was confirmed by metabolic labeling with (75)Se, and expression of SelT was additionally documented in immunoblot assays. SelT and SelR did not have homology to previously characterized proteins, but their putative homologs were detected in various organisms. SelR homologs were present in every organism characterized by complete genome sequencing. The data suggest applicability of SECISearch for identification of new selenoprotein genes in nucleotide data bases.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d1597667c614526ba0ceede9a3ecc54", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[48, 48], [82, 82]], "char_spans": [[311, 315], [517, 521]]}]}], "context_tokens": [["Mammalian", 0], ["selenium", 10], ["-", 18], ["containing", 19], ["proteins", 30], ["identified", 39], ["thus", 50], ["far", 55], ["contain", 59], ["selenium", 67], ["in", 76], ["the", 79], ["form", 83], ["of", 88], ["a", 91], ["selenocysteine", 93], ["residue", 108], ["encoded", 116], ["by", 124], ["UGA", 127], [".", 130], ["These", 132], ["proteins", 138], ["lack", 147], ["common", 152], ["amino", 159], ["acid", 165], ["sequence", 170], ["motifs", 179], [",", 185], ["but", 187], ["3'-untranslated", 191], ["regions", 207], ["of", 215], ["selenoprotein", 218], ["genes", 232], ["contain", 238], ["a", 246], ["common", 248], ["stem", 255], ["-", 259], ["loop", 260], ["structure", 265], [",", 274], ["selenocysteine", 276], ["insertion", 291], ["sequence", 301], ["(", 310], ["SECIS", 311], [")", 316], ["element", 318], [",", 325], ["that", 327], ["is", 332], ["necessary", 335], ["for", 345], ["decoding", 349], ["UGA", 358], ["as", 362], ["selenocysteine", 365], ["rather", 380], ["than", 387], ["a", 392], ["stop", 394], ["signal", 399], [".", 405], ["We", 407], ["describe", 410], ["here", 419], ["a", 424], ["computer", 426], ["program", 435], [",", 442], ["SECISearch", 444], [",", 454], ["that", 456], ["identifies", 461], ["mammalian", 472], ["selenoprotein", 482], ["genes", 496], ["by", 502], ["recognizing", 505], ["SECIS", 517], ["elements", 523], ["on", 532], ["the", 535], ["basis", 539], ["of", 545], ["their", 548], ["primary", 554], ["and", 562], ["secondary", 566], ["structures", 576], ["and", 587], ["free", 591], ["energy", 596], ["requirements", 603], [".", 615], ["When", 617], ["SECISearch", 622], ["was", 633], ["applied", 637], ["to", 645], ["search", 648], ["human", 655], ["dbEST", 661], [",", 666], ["two", 668], ["new", 672], ["mammalian", 676], ["selenoproteins", 686], [",", 700], ["designated", 702], ["SelT", 713], ["and", 718], ["SelR", 722], [",", 726], ["were", 728], ["identified", 733], [".", 743], ["We", 745], ["determined", 748], ["their", 759], ["cDNA", 765], ["sequences", 770], ["and", 780], ["expressed", 784], ["them", 794], ["in", 799], ["a", 802], ["monkey", 804], ["cell", 811], ["line", 816], ["as", 821], ["fusion", 824], ["proteins", 831], ["with", 840], ["a", 845], ["green", 847], ["fluorescent", 853], ["protein", 865], [".", 872], ["Incorporation", 874], ["of", 888], ["selenium", 891], ["into", 900], ["new", 905], ["proteins", 909], ["was", 918], ["confirmed", 922], ["by", 932], ["metabolic", 935], ["labeling", 945], ["with", 954], ["(", 959], ["75)Se", 960], [",", 965], ["and", 967], ["expression", 971], ["of", 982], ["SelT", 985], ["was", 990], ["additionally", 994], ["documented", 1007], ["in", 1018], ["immunoblot", 1021], ["assays", 1032], [".", 1038], ["SelT", 1040], ["and", 1045], ["SelR", 1049], ["did", 1054], ["not", 1058], ["have", 1062], ["homology", 1067], ["to", 1076], ["previously", 1079], ["characterized", 1090], ["proteins", 1104], [",", 1112], ["but", 1114], ["their", 1118], ["putative", 1124], ["homologs", 1133], ["were", 1142], ["detected", 1147], ["in", 1156], ["various", 1159], ["organisms", 1167], [".", 1176], ["SelR", 1178], ["homologs", 1183], ["were", 1192], ["present", 1197], ["in", 1205], ["every", 1208], ["organism", 1214], ["characterized", 1223], ["by", 1237], ["complete", 1240], ["genome", 1249], ["sequencing", 1256], [".", 1266], ["The", 1268], ["data", 1272], ["suggest", 1277], ["applicability", 1285], ["of", 1299], ["SECISearch", 1302], ["for", 1313], ["identification", 1317], ["of", 1332], ["new", 1335], ["selenoprotein", 1339], ["genes", 1353], ["in", 1359], ["nucleotide", 1362], ["data", 1373], ["bases", 1378], [".", 1383]]}
{"context": "Chronic inflammation contributes to a wide variety of human disorders. In the stomach, longstanding gastritis often results in structural alterations in the gastric mucosa, including metaplastic changes and gastric cancers. Therefore, it is important to elucidate factors that are involved in gastric inflammation. Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins. Here, we have demonstrated that Nrdc crucially regulates gastric inflammation caused by Helicobacter felis infection or forced expression of prostaglandin E", "qas": [{"question": "Which is the enzymatic activity of nardilysin?", "answers": ["Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins."], "qid": "133771e8d5b9448681074f5d120771a8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["nardilysin", 35], ["?", 45]], "detected_answers": [{"text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.", "token_spans": [[49, 93]], "char_spans": [[315, 595]]}]}], "context_tokens": [["Chronic", 0], ["inflammation", 8], ["contributes", 21], ["to", 33], ["a", 36], ["wide", 38], ["variety", 43], ["of", 51], ["human", 54], ["disorders", 60], [".", 69], ["In", 71], ["the", 74], ["stomach", 78], [",", 85], ["longstanding", 87], ["gastritis", 100], ["often", 110], ["results", 116], ["in", 124], ["structural", 127], ["alterations", 138], ["in", 150], ["the", 153], ["gastric", 157], ["mucosa", 165], [",", 171], ["including", 173], ["metaplastic", 183], ["changes", 195], ["and", 203], ["gastric", 207], ["cancers", 215], [".", 222], ["Therefore", 224], [",", 233], ["it", 235], ["is", 238], ["important", 241], ["to", 251], ["elucidate", 254], ["factors", 264], ["that", 272], ["are", 277], ["involved", 281], ["in", 290], ["gastric", 293], ["inflammation", 301], [".", 313], ["Nardilysin", 315], ["(", 326], ["N", 327], ["-", 328], ["arginine", 329], ["dibasic", 338], ["convertase", 346], [";", 356], ["Nrdc", 358], [")", 362], ["is", 364], ["a", 367], ["metalloendopeptidase", 369], ["of", 390], ["the", 393], ["M16", 397], ["family", 401], ["that", 408], ["promotes", 413], ["ectodomain", 422], ["shedding", 433], ["of", 442], ["the", 445], ["precursor", 449], ["forms", 459], ["of", 465], ["various", 468], ["growth", 476], ["factors", 483], ["and", 491], ["cytokines", 495], ["by", 505], ["enhancing", 508], ["the", 518], ["protease", 522], ["activities", 531], ["of", 542], ["a", 545], ["disintegrin", 547], ["and", 559], ["metalloproteinase", 563], ["(", 581], ["ADAM", 582], [")", 586], ["proteins", 588], [".", 596], ["Here", 598], [",", 602], ["we", 604], ["have", 607], ["demonstrated", 612], ["that", 625], ["Nrdc", 630], ["crucially", 635], ["regulates", 645], ["gastric", 655], ["inflammation", 663], ["caused", 676], ["by", 683], ["Helicobacter", 686], ["felis", 699], ["infection", 705], ["or", 715], ["forced", 718], ["expression", 725], ["of", 736], ["prostaglandin", 739], ["E", 753]]}
{"context": "The Romano-Ward long-QT Syndrome (LQTS) is an autosomal dominant inherited trait characterized by prolonged QT interval on ECG, life-threatening arrhythmias, syncope, and sudden death in affected individuals. A gene responsible for this disorder has been shown to be linked to the Harvey ras-1 locus (H-ras-1) DNA marker on the short arm of chromosome 11 (11p) in 7 families. The purpose of this study was to determine, by analyzing 23 families with LQTS for linkage to chromosome 11p, whether evidence exists for more than one gene causing LQTS (ie, locus heterogeneity). Twenty-three families (262 family members) were clinically evaluated using medical histories, ECGs, and Holter recordings. Each corrected QT interval (QTc) were determined using Bazett's formula. Blood for DNA extraction and cell line immortalization was obtained after informed consent. Southern blotting and polymerase chain reaction were performed, and linkage analysis carried out using the LINKAGE computer program (v 5.03). Genetic heterogeneity was determined using the HOMOG 2 (v 2.51) computer program. Twenty-three families were studied for evidence of linkage to chromosome 11p using the H-ras-1 locus probe pTBB-2 and multiple flanking markers, including tyrosine hydroxylase (TH). Two-point linkage analysis using pTBB-2 and TH markers was consistent with linkage in 15 of 23 families, with the maximum single-family LOD score of +3.038 occurring at theta = 0. However, 8 of 23 families had negative LOD scores, with the values in 4 families being less than -2 at theta = 0, consistent with exclusion of linkage. Analysis with the HOMOG program was consistent with genetic heterogeneity (P < .0001). Multipoint linkage data using pTBB-2 and TH were also examined for evidence of heterogeneity. HOMOG analysis of multipoint LOD scores from 100 cM surrounding the H-ras-1 locus also supported heterogeneity (P < .001). In the 23 families with LQTS analyzed for linkage to the H-ras-1 locus on chromosome 11p15.5, 15 of 23 families had LOD scores consistent with linkage. The remaining 8 of 23 families had negative LOD scores, 4 of which were definitively excluded from linkage. Thus, genetic heterogeneity is definitively (P < .001) demonstrated for this disorder.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "16cda57d6f444810a77096b293729095", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[13, 14]], "char_spans": [[46, 63]]}]}], "context_tokens": [["The", 0], ["Romano", 4], ["-", 10], ["Ward", 11], ["long", 16], ["-", 20], ["QT", 21], ["Syndrome", 24], ["(", 33], ["LQTS", 34], [")", 38], ["is", 40], ["an", 43], ["autosomal", 46], ["dominant", 56], ["inherited", 65], ["trait", 75], ["characterized", 81], ["by", 95], ["prolonged", 98], ["QT", 108], ["interval", 111], ["on", 120], ["ECG", 123], [",", 126], ["life", 128], ["-", 132], ["threatening", 133], ["arrhythmias", 145], [",", 156], ["syncope", 158], [",", 165], ["and", 167], ["sudden", 171], ["death", 178], ["in", 184], ["affected", 187], ["individuals", 196], [".", 207], ["A", 209], ["gene", 211], ["responsible", 216], ["for", 228], ["this", 232], ["disorder", 237], ["has", 246], ["been", 250], ["shown", 255], ["to", 261], ["be", 264], ["linked", 267], ["to", 274], ["the", 277], ["Harvey", 281], ["ras-1", 288], ["locus", 294], ["(", 300], ["H", 301], ["-", 302], ["ras-1", 303], [")", 308], ["DNA", 310], ["marker", 314], ["on", 321], ["the", 324], ["short", 328], ["arm", 334], ["of", 338], ["chromosome", 341], ["11", 352], ["(", 355], ["11p", 356], [")", 359], ["in", 361], ["7", 364], ["families", 366], [".", 374], ["The", 376], ["purpose", 380], ["of", 388], ["this", 391], ["study", 396], ["was", 402], ["to", 406], ["determine", 409], [",", 418], ["by", 420], ["analyzing", 423], ["23", 433], ["families", 436], ["with", 445], ["LQTS", 450], ["for", 455], ["linkage", 459], ["to", 467], ["chromosome", 470], ["11p", 481], [",", 484], ["whether", 486], ["evidence", 494], ["exists", 503], ["for", 510], ["more", 514], ["than", 519], ["one", 524], ["gene", 528], ["causing", 533], ["LQTS", 541], ["(", 546], ["ie", 547], [",", 549], ["locus", 551], ["heterogeneity", 557], [")", 570], [".", 571], ["Twenty", 573], ["-", 579], ["three", 580], ["families", 586], ["(", 595], ["262", 596], ["family", 600], ["members", 607], [")", 614], ["were", 616], ["clinically", 621], ["evaluated", 632], ["using", 642], ["medical", 648], ["histories", 656], [",", 665], ["ECGs", 667], [",", 671], ["and", 673], ["Holter", 677], ["recordings", 684], [".", 694], ["Each", 696], ["corrected", 701], ["QT", 711], ["interval", 714], ["(", 723], ["QTc", 724], [")", 727], ["were", 729], ["determined", 734], ["using", 745], ["Bazett", 751], ["'s", 757], ["formula", 760], [".", 767], ["Blood", 769], ["for", 775], ["DNA", 779], ["extraction", 783], ["and", 794], ["cell", 798], ["line", 803], ["immortalization", 808], ["was", 824], ["obtained", 828], ["after", 837], ["informed", 843], ["consent", 852], [".", 859], ["Southern", 861], ["blotting", 870], ["and", 879], ["polymerase", 883], ["chain", 894], ["reaction", 900], ["were", 909], ["performed", 914], [",", 923], ["and", 925], ["linkage", 929], ["analysis", 937], ["carried", 946], ["out", 954], ["using", 958], ["the", 964], ["LINKAGE", 968], ["computer", 976], ["program", 985], ["(", 993], ["v", 994], ["5.03", 996], [")", 1000], [".", 1001], ["Genetic", 1003], ["heterogeneity", 1011], ["was", 1025], ["determined", 1029], ["using", 1040], ["the", 1046], ["HOMOG", 1050], ["2", 1056], ["(", 1058], ["v", 1059], ["2.51", 1061], [")", 1065], ["computer", 1067], ["program", 1076], [".", 1083], ["Twenty", 1085], ["-", 1091], ["three", 1092], ["families", 1098], ["were", 1107], ["studied", 1112], ["for", 1120], ["evidence", 1124], ["of", 1133], ["linkage", 1136], ["to", 1144], ["chromosome", 1147], ["11p", 1158], ["using", 1162], ["the", 1168], ["H", 1172], ["-", 1173], ["ras-1", 1174], ["locus", 1180], ["probe", 1186], ["pTBB-2", 1192], ["and", 1199], ["multiple", 1203], ["flanking", 1212], ["markers", 1221], [",", 1228], ["including", 1230], ["tyrosine", 1240], ["hydroxylase", 1249], ["(", 1261], ["TH", 1262], [")", 1264], [".", 1265], ["Two", 1267], ["-", 1270], ["point", 1271], ["linkage", 1277], ["analysis", 1285], ["using", 1294], ["pTBB-2", 1300], ["and", 1307], ["TH", 1311], ["markers", 1314], ["was", 1322], ["consistent", 1326], ["with", 1337], ["linkage", 1342], ["in", 1350], ["15", 1353], ["of", 1356], ["23", 1359], ["families", 1362], [",", 1370], ["with", 1372], ["the", 1377], ["maximum", 1381], ["single", 1389], ["-", 1395], ["family", 1396], ["LOD", 1403], ["score", 1407], ["of", 1413], ["+3.038", 1416], ["occurring", 1423], ["at", 1433], ["theta", 1436], ["=", 1442], ["0", 1444], [".", 1445], ["However", 1447], [",", 1454], ["8", 1456], ["of", 1458], ["23", 1461], ["families", 1464], ["had", 1473], ["negative", 1477], ["LOD", 1486], ["scores", 1490], [",", 1496], ["with", 1498], ["the", 1503], ["values", 1507], ["in", 1514], ["4", 1517], ["families", 1519], ["being", 1528], ["less", 1534], ["than", 1539], ["-2", 1544], ["at", 1547], ["theta", 1550], ["=", 1556], ["0", 1558], [",", 1559], ["consistent", 1561], ["with", 1572], ["exclusion", 1577], ["of", 1587], ["linkage", 1590], [".", 1597], ["Analysis", 1599], ["with", 1608], ["the", 1613], ["HOMOG", 1617], ["program", 1623], ["was", 1631], ["consistent", 1635], ["with", 1646], ["genetic", 1651], ["heterogeneity", 1659], ["(", 1673], ["P", 1674], ["<", 1676], [".0001", 1678], [")", 1683], [".", 1684], ["Multipoint", 1686], ["linkage", 1697], ["data", 1705], ["using", 1710], ["pTBB-2", 1716], ["and", 1723], ["TH", 1727], ["were", 1730], ["also", 1735], ["examined", 1740], ["for", 1749], ["evidence", 1753], ["of", 1762], ["heterogeneity", 1765], [".", 1778], ["HOMOG", 1780], ["analysis", 1786], ["of", 1795], ["multipoint", 1798], ["LOD", 1809], ["scores", 1813], ["from", 1820], ["100", 1825], ["cM", 1829], ["surrounding", 1832], ["the", 1844], ["H", 1848], ["-", 1849], ["ras-1", 1850], ["locus", 1856], ["also", 1862], ["supported", 1867], ["heterogeneity", 1877], ["(", 1891], ["P", 1892], ["<", 1894], [".001", 1896], [")", 1900], [".", 1901], ["In", 1903], ["the", 1906], ["23", 1910], ["families", 1913], ["with", 1922], ["LQTS", 1927], ["analyzed", 1932], ["for", 1941], ["linkage", 1945], ["to", 1953], ["the", 1956], ["H", 1960], ["-", 1961], ["ras-1", 1962], ["locus", 1968], ["on", 1974], ["chromosome", 1977], ["11p15.5", 1988], [",", 1995], ["15", 1997], ["of", 2000], ["23", 2003], ["families", 2006], ["had", 2015], ["LOD", 2019], ["scores", 2023], ["consistent", 2030], ["with", 2041], ["linkage", 2046], [".", 2053], ["The", 2055], ["remaining", 2059], ["8", 2069], ["of", 2071], ["23", 2074], ["families", 2077], ["had", 2086], ["negative", 2090], ["LOD", 2099], ["scores", 2103], [",", 2109], ["4", 2111], ["of", 2113], ["which", 2116], ["were", 2122], ["definitively", 2127], ["excluded", 2140], ["from", 2149], ["linkage", 2154], [".", 2161], ["Thus", 2163], [",", 2167], ["genetic", 2169], ["heterogeneity", 2177], ["is", 2191], ["definitively", 2194], ["(", 2207], ["P", 2208], ["<", 2210], [".001", 2212], [")", 2216], ["demonstrated", 2218], ["for", 2231], ["this", 2235], ["disorder", 2240], [".", 2248]]}
{"context": "X monosomic mice (39,XO) have a remarkably mild phenotype when compared to women with Turner syndrome (45,XO). The generally accepted hypothesis to explain this discrepancy is that the number of genes on the mouse X chromosome which escape X inactivation, and thus are expressed at higher levels in females, is very small. However this hypothesis has never been tested and only a small number of genes have been assayed for their X-inactivation status in the mouse. We performed a global expression analysis in four somatic tissues (brain, liver, kidney and muscle) of adult 40,XX and 39,XO mice using the Illumina Mouse WG-6 v1_1 Expression BeadChip and an extensive validation by quantitative real time PCR, in order to identify which genes are expressed from both X chromosomes. We identified several genes on the X chromosome which are overexpressed in XX females, including those previously reported as escaping X inactivation, as well as new candidates. However, the results obtained by microarray and qPCR were not fully concordant, illustrating the difficulty in ascertaining modest fold changes, such as those expected for genes escaping X inactivation. Remarkably, considerable variation was observed between tissues, suggesting that inactivation patterns may be tissue-dependent. Our analysis also exposed several autosomal genes involved in mitochondrial metabolism and in protein translation which are differentially expressed between XX and XO mice, revealing secondary transcriptional changes to the alteration in X chromosome dosage. Our results support the prediction that the mouse inactive X chromosome is largely silent, while providing a list of the genes potentially escaping X inactivation in rodents. Although the lower expression of X-linked genes in XO mice may not be relevant in the particular tissues/systems which are affected in human X chromosome monosomy, genes deregulated in XO mice are good candidates for further study in an involvement in Turner Syndrome phenotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f60eb4dfa5774b8c8a56567d0989deff", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [43, 43], [149, 149], [203, 203], [286, 286], [140, 140], [164, 164], [39, 39], [296, 296], [318, 318], [258, 258], [79, 79], [271, 271]], "char_spans": [[0, 0], [240, 240], [817, 817], [1147, 1147], [1698, 1698], [767, 767], [917, 917], [214, 214], [1758, 1758], [1866, 1866], [1529, 1529], [430, 430], [1609, 1609]]}]}], "context_tokens": [["X", 0], ["monosomic", 2], ["mice", 12], ["(", 17], ["39,XO", 18], [")", 23], ["have", 25], ["a", 30], ["remarkably", 32], ["mild", 43], ["phenotype", 48], ["when", 58], ["compared", 63], ["to", 72], ["women", 75], ["with", 81], ["Turner", 86], ["syndrome", 93], ["(", 102], ["45,XO", 103], [")", 108], [".", 109], ["The", 111], ["generally", 115], ["accepted", 125], ["hypothesis", 134], ["to", 145], ["explain", 148], ["this", 156], ["discrepancy", 161], ["is", 173], ["that", 176], ["the", 181], ["number", 185], ["of", 192], ["genes", 195], ["on", 201], ["the", 204], ["mouse", 208], ["X", 214], ["chromosome", 216], ["which", 227], ["escape", 233], ["X", 240], ["inactivation", 242], [",", 254], ["and", 256], ["thus", 260], ["are", 265], ["expressed", 269], ["at", 279], ["higher", 282], ["levels", 289], ["in", 296], ["females", 299], [",", 306], ["is", 308], ["very", 311], ["small", 316], [".", 321], ["However", 323], ["this", 331], ["hypothesis", 336], ["has", 347], ["never", 351], ["been", 357], ["tested", 362], ["and", 369], ["only", 373], ["a", 378], ["small", 380], ["number", 386], ["of", 393], ["genes", 396], ["have", 402], ["been", 407], ["assayed", 412], ["for", 420], ["their", 424], ["X", 430], ["-", 431], ["inactivation", 432], ["status", 445], ["in", 452], ["the", 455], ["mouse", 459], [".", 464], ["We", 466], ["performed", 469], ["a", 479], ["global", 481], ["expression", 488], ["analysis", 499], ["in", 508], ["four", 511], ["somatic", 516], ["tissues", 524], ["(", 532], ["brain", 533], [",", 538], ["liver", 540], [",", 545], ["kidney", 547], ["and", 554], ["muscle", 558], [")", 564], ["of", 566], ["adult", 569], ["40,XX", 575], ["and", 581], ["39,XO", 585], ["mice", 591], ["using", 596], ["the", 602], ["Illumina", 606], ["Mouse", 615], ["WG-6", 621], ["v1_1", 626], ["Expression", 631], ["BeadChip", 642], ["and", 651], ["an", 655], ["extensive", 658], ["validation", 668], ["by", 679], ["quantitative", 682], ["real", 695], ["time", 700], ["PCR", 705], [",", 708], ["in", 710], ["order", 713], ["to", 719], ["identify", 722], ["which", 731], ["genes", 737], ["are", 743], ["expressed", 747], ["from", 757], ["both", 762], ["X", 767], ["chromosomes", 769], [".", 780], ["We", 782], ["identified", 785], ["several", 796], ["genes", 804], ["on", 810], ["the", 813], ["X", 817], ["chromosome", 819], ["which", 830], ["are", 836], ["overexpressed", 840], ["in", 854], ["XX", 857], ["females", 860], [",", 867], ["including", 869], ["those", 879], ["previously", 885], ["reported", 896], ["as", 905], ["escaping", 908], ["X", 917], ["inactivation", 919], [",", 931], ["as", 933], ["well", 936], ["as", 941], ["new", 944], ["candidates", 948], [".", 958], ["However", 960], [",", 967], ["the", 969], ["results", 973], ["obtained", 981], ["by", 990], ["microarray", 993], ["and", 1004], ["qPCR", 1008], ["were", 1013], ["not", 1018], ["fully", 1022], ["concordant", 1028], [",", 1038], ["illustrating", 1040], ["the", 1053], ["difficulty", 1057], ["in", 1068], ["ascertaining", 1071], ["modest", 1084], ["fold", 1091], ["changes", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["those", 1113], ["expected", 1119], ["for", 1128], ["genes", 1132], ["escaping", 1138], ["X", 1147], ["inactivation", 1149], [".", 1161], ["Remarkably", 1163], [",", 1173], ["considerable", 1175], ["variation", 1188], ["was", 1198], ["observed", 1202], ["between", 1211], ["tissues", 1219], [",", 1226], ["suggesting", 1228], ["that", 1239], ["inactivation", 1244], ["patterns", 1257], ["may", 1266], ["be", 1270], ["tissue", 1273], ["-", 1279], ["dependent", 1280], [".", 1289], ["Our", 1291], ["analysis", 1295], ["also", 1304], ["exposed", 1309], ["several", 1317], ["autosomal", 1325], ["genes", 1335], ["involved", 1341], ["in", 1350], ["mitochondrial", 1353], ["metabolism", 1367], ["and", 1378], ["in", 1382], ["protein", 1385], ["translation", 1393], ["which", 1405], ["are", 1411], ["differentially", 1415], ["expressed", 1430], ["between", 1440], ["XX", 1448], ["and", 1451], ["XO", 1455], ["mice", 1458], [",", 1462], ["revealing", 1464], ["secondary", 1474], ["transcriptional", 1484], ["changes", 1500], ["to", 1508], ["the", 1511], ["alteration", 1515], ["in", 1526], ["X", 1529], ["chromosome", 1531], ["dosage", 1542], [".", 1548], ["Our", 1550], ["results", 1554], ["support", 1562], ["the", 1570], ["prediction", 1574], ["that", 1585], ["the", 1590], ["mouse", 1594], ["inactive", 1600], ["X", 1609], ["chromosome", 1611], ["is", 1622], ["largely", 1625], ["silent", 1633], [",", 1639], ["while", 1641], ["providing", 1647], ["a", 1657], ["list", 1659], ["of", 1664], ["the", 1667], ["genes", 1671], ["potentially", 1677], ["escaping", 1689], ["X", 1698], ["inactivation", 1700], ["in", 1713], ["rodents", 1716], [".", 1723], ["Although", 1725], ["the", 1734], ["lower", 1738], ["expression", 1744], ["of", 1755], ["X", 1758], ["-", 1759], ["linked", 1760], ["genes", 1767], ["in", 1773], ["XO", 1776], ["mice", 1779], ["may", 1784], ["not", 1788], ["be", 1792], ["relevant", 1795], ["in", 1804], ["the", 1807], ["particular", 1811], ["tissues", 1822], ["/", 1829], ["systems", 1830], ["which", 1838], ["are", 1844], ["affected", 1848], ["in", 1857], ["human", 1860], ["X", 1866], ["chromosome", 1868], ["monosomy", 1879], [",", 1887], ["genes", 1889], ["deregulated", 1895], ["in", 1907], ["XO", 1910], ["mice", 1913], ["are", 1918], ["good", 1922], ["candidates", 1927], ["for", 1938], ["further", 1942], ["study", 1950], ["in", 1956], ["an", 1959], ["involvement", 1962], ["in", 1974], ["Turner", 1977], ["Syndrome", 1984], ["phenotype", 1993], [".", 2002]]}
{"context": "We report a novel mutation in the XK gene (XK) in a Japanese patient with McLeod syndrome. A 50-year-old man showed progressive muscular atrophy, choreic movement, elevated level of serum creatinine kinase, and acanthocytosis. The expression level of all the Kell antigens in erythrocyte was decreased and molecular analysis revealed a single-base (T) deletion at the nucleotide position 1095 in XK. This deletion caused a frameshift in translation, leading to a premature stop codon at the amino acid position 408. We conclude this single-base deletion causes defective Kx protein, which is responsible for the McLeod phenotype in this patient.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "682f059c5e1247ec92d678ce3cc5a4cc", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[7, 7], [73, 73], [10, 10]], "char_spans": [[34, 35], [396, 397], [43, 44]]}]}], "context_tokens": [["We", 0], ["report", 3], ["a", 10], ["novel", 12], ["mutation", 18], ["in", 27], ["the", 30], ["XK", 34], ["gene", 37], ["(", 42], ["XK", 43], [")", 45], ["in", 47], ["a", 50], ["Japanese", 52], ["patient", 61], ["with", 69], ["McLeod", 74], ["syndrome", 81], [".", 89], ["A", 91], ["50-year", 93], ["-", 100], ["old", 101], ["man", 105], ["showed", 109], ["progressive", 116], ["muscular", 128], ["atrophy", 137], [",", 144], ["choreic", 146], ["movement", 154], [",", 162], ["elevated", 164], ["level", 173], ["of", 179], ["serum", 182], ["creatinine", 188], ["kinase", 199], [",", 205], ["and", 207], ["acanthocytosis", 211], [".", 225], ["The", 227], ["expression", 231], ["level", 242], ["of", 248], ["all", 251], ["the", 255], ["Kell", 259], ["antigens", 264], ["in", 273], ["erythrocyte", 276], ["was", 288], ["decreased", 292], ["and", 302], ["molecular", 306], ["analysis", 316], ["revealed", 325], ["a", 334], ["single", 336], ["-", 342], ["base", 343], ["(", 348], ["T", 349], [")", 350], ["deletion", 352], ["at", 361], ["the", 364], ["nucleotide", 368], ["position", 379], ["1095", 388], ["in", 393], ["XK", 396], [".", 398], ["This", 400], ["deletion", 405], ["caused", 414], ["a", 421], ["frameshift", 423], ["in", 434], ["translation", 437], [",", 448], ["leading", 450], ["to", 458], ["a", 461], ["premature", 463], ["stop", 473], ["codon", 478], ["at", 484], ["the", 487], ["amino", 491], ["acid", 497], ["position", 502], ["408", 511], [".", 514], ["We", 516], ["conclude", 519], ["this", 528], ["single", 533], ["-", 539], ["base", 540], ["deletion", 545], ["causes", 554], ["defective", 561], ["Kx", 571], ["protein", 574], [",", 581], ["which", 583], ["is", 589], ["responsible", 592], ["for", 604], ["the", 608], ["McLeod", 612], ["phenotype", 619], ["in", 629], ["this", 632], ["patient", 637], [".", 644]]}
{"context": "Insulin is the cornerstone of type 1 diabetes mellitus (T1DM) therapy. However, it cannot achieve a delay in the onset or evolution of this condition, while cardiovascular morbidity remains an unquestionable threat. In this review, the authors discuss gevokizumab (XOMA 052), a recombinant monoclonal antibody that can neutralize human IL-1\u03b2 by binding to it. This is relevant, because this IL has been associated with \u03b2-cell toxicity in both diabetes types. Moreover, gevokizumab presents two major advantages: it spares IL-1\u03b1 and it exhibits favorable pharmacokinetic properties. Gevokizumab has already proven its safety and efficacy in improving glycemic control, \u03b2 cell function and inflammation markers in clinical trials in diabetic patients. Despite the very promising characteristics of gevokizumab, important questions remain to be answered. One important question is what to expect from a combination of this agent with insulin and if there is a subset of patients that might respond more favorably to treatment. We also need to know at what stage in the natural history of T1DM could gevokizumab be most efficacious, as well as its potential effects on cardiovascular outcomes.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "c44c66126f324ce3acbc22cbc8a73352", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[60, 60]], "char_spans": [[336, 340]]}]}], "context_tokens": [["Insulin", 0], ["is", 8], ["the", 11], ["cornerstone", 15], ["of", 27], ["type", 30], ["1", 35], ["diabetes", 37], ["mellitus", 46], ["(", 55], ["T1DM", 56], [")", 60], ["therapy", 62], [".", 69], ["However", 71], [",", 78], ["it", 80], ["can", 83], ["not", 86], ["achieve", 90], ["a", 98], ["delay", 100], ["in", 106], ["the", 109], ["onset", 113], ["or", 119], ["evolution", 122], ["of", 132], ["this", 135], ["condition", 140], [",", 149], ["while", 151], ["cardiovascular", 157], ["morbidity", 172], ["remains", 182], ["an", 190], ["unquestionable", 193], ["threat", 208], [".", 214], ["In", 216], ["this", 219], ["review", 224], [",", 230], ["the", 232], ["authors", 236], ["discuss", 244], ["gevokizumab", 252], ["(", 264], ["XOMA", 265], ["052", 270], [")", 273], [",", 274], ["a", 276], ["recombinant", 278], ["monoclonal", 290], ["antibody", 301], ["that", 310], ["can", 315], ["neutralize", 319], ["human", 330], ["IL-1\u03b2", 336], ["by", 342], ["binding", 345], ["to", 353], ["it", 356], [".", 358], ["This", 360], ["is", 365], ["relevant", 368], [",", 376], ["because", 378], ["this", 386], ["IL", 391], ["has", 394], ["been", 398], ["associated", 403], ["with", 414], ["\u03b2", 419], ["-", 420], ["cell", 421], ["toxicity", 426], ["in", 435], ["both", 438], ["diabetes", 443], ["types", 452], [".", 457], ["Moreover", 459], [",", 467], ["gevokizumab", 469], ["presents", 481], ["two", 490], ["major", 494], ["advantages", 500], [":", 510], ["it", 512], ["spares", 515], ["IL-1\u03b1", 522], ["and", 528], ["it", 532], ["exhibits", 535], ["favorable", 544], ["pharmacokinetic", 554], ["properties", 570], [".", 580], ["Gevokizumab", 582], ["has", 594], ["already", 598], ["proven", 606], ["its", 613], ["safety", 617], ["and", 624], ["efficacy", 628], ["in", 637], ["improving", 640], ["glycemic", 650], ["control", 659], [",", 666], ["\u03b2", 668], ["cell", 670], ["function", 675], ["and", 684], ["inflammation", 688], ["markers", 701], ["in", 709], ["clinical", 712], ["trials", 721], ["in", 728], ["diabetic", 731], ["patients", 740], [".", 748], ["Despite", 750], ["the", 758], ["very", 762], ["promising", 767], ["characteristics", 777], ["of", 793], ["gevokizumab", 796], [",", 807], ["important", 809], ["questions", 819], ["remain", 829], ["to", 836], ["be", 839], ["answered", 842], [".", 850], ["One", 852], ["important", 856], ["question", 866], ["is", 875], ["what", 878], ["to", 883], ["expect", 886], ["from", 893], ["a", 898], ["combination", 900], ["of", 912], ["this", 915], ["agent", 920], ["with", 926], ["insulin", 931], ["and", 939], ["if", 943], ["there", 946], ["is", 952], ["a", 955], ["subset", 957], ["of", 964], ["patients", 967], ["that", 976], ["might", 981], ["respond", 987], ["more", 995], ["favorably", 1000], ["to", 1010], ["treatment", 1013], [".", 1022], ["We", 1024], ["also", 1027], ["need", 1032], ["to", 1037], ["know", 1040], ["at", 1045], ["what", 1048], ["stage", 1053], ["in", 1059], ["the", 1062], ["natural", 1066], ["history", 1074], ["of", 1082], ["T1DM", 1085], ["could", 1090], ["gevokizumab", 1096], ["be", 1108], ["most", 1111], ["efficacious", 1116], [",", 1127], ["as", 1129], ["well", 1132], ["as", 1137], ["its", 1140], ["potential", 1144], ["effects", 1154], ["on", 1162], ["cardiovascular", 1165], ["outcomes", 1180], [".", 1188]]}
{"context": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome. Fluorescent in situ hybridization analysis (FISH), MLPA or multiplex quantitative PCR allow detection of total/partial NSD1 deletions and direct sequencing allows detection of NSD1 mutations. We describe two boys with Sotos syndrome in whom PCR amplification and direct sequencing of the NSD1 gene identified two novel mutations not previously described: c.4736dupG in exon 12 and c.3938_3939insT in exon 7. In addition to the cardinal and major features of the syndrome (abnormal facial appearance, overgrowth, cardiac anomalies, renal anomalies, hypotonia, neonatal jaundice, seizures and brain MRI abnormalities) in both patients, one boy also had cryptorchidism and vertebral anomalies, features considered not common. Despite the wide range of possible combinations of phenotypic features, molecular analysis can correctly identify Sotos syndrome.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "da2112b55fe74ffe80afbc48f42143f7", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[5, 6], [72, 73]], "char_spans": [[31, 39], [415, 423]]}]}], "context_tokens": [["Mutations", 0], ["and", 10], ["deletions", 14], ["of", 24], ["the", 27], ["NSD1", 31], ["gene", 36], [",", 40], ["located", 42], ["on", 50], ["chromosome", 53], ["5q35", 64], [",", 68], ["are", 70], ["responsible", 74], ["for", 86], ["over", 90], ["90", 95], ["%", 97], ["of", 99], ["cases", 102], ["of", 108], ["Sotos", 111], ["syndrome", 117], [".", 125], ["Fluorescent", 127], ["in", 139], ["situ", 142], ["hybridization", 147], ["analysis", 161], ["(", 170], ["FISH", 171], [")", 175], [",", 176], ["MLPA", 178], ["or", 183], ["multiplex", 186], ["quantitative", 196], ["PCR", 209], ["allow", 213], ["detection", 219], ["of", 229], ["total", 232], ["/", 237], ["partial", 238], ["NSD1", 246], ["deletions", 251], ["and", 261], ["direct", 265], ["sequencing", 272], ["allows", 283], ["detection", 290], ["of", 300], ["NSD1", 303], ["mutations", 308], [".", 317], ["We", 319], ["describe", 322], ["two", 331], ["boys", 335], ["with", 340], ["Sotos", 345], ["syndrome", 351], ["in", 360], ["whom", 363], ["PCR", 368], ["amplification", 372], ["and", 386], ["direct", 390], ["sequencing", 397], ["of", 408], ["the", 411], ["NSD1", 415], ["gene", 420], ["identified", 425], ["two", 436], ["novel", 440], ["mutations", 446], ["not", 456], ["previously", 460], ["described", 471], [":", 480], ["c.4736dupG", 482], ["in", 493], ["exon", 496], ["12", 501], ["and", 504], ["c.3938_3939insT", 508], ["in", 524], ["exon", 527], ["7", 532], [".", 533], ["In", 535], ["addition", 538], ["to", 547], ["the", 550], ["cardinal", 554], ["and", 563], ["major", 567], ["features", 573], ["of", 582], ["the", 585], ["syndrome", 589], ["(", 598], ["abnormal", 599], ["facial", 608], ["appearance", 615], [",", 625], ["overgrowth", 627], [",", 637], ["cardiac", 639], ["anomalies", 647], [",", 656], ["renal", 658], ["anomalies", 664], [",", 673], ["hypotonia", 675], [",", 684], ["neonatal", 686], ["jaundice", 695], [",", 703], ["seizures", 705], ["and", 714], ["brain", 718], ["MRI", 724], ["abnormalities", 728], [")", 741], ["in", 743], ["both", 746], ["patients", 751], [",", 759], ["one", 761], ["boy", 765], ["also", 769], ["had", 774], ["cryptorchidism", 778], ["and", 793], ["vertebral", 797], ["anomalies", 807], [",", 816], ["features", 818], ["considered", 827], ["not", 838], ["common", 842], [".", 848], ["Despite", 850], ["the", 858], ["wide", 862], ["range", 867], ["of", 873], ["possible", 876], ["combinations", 885], ["of", 898], ["phenotypic", 901], ["features", 912], [",", 920], ["molecular", 922], ["analysis", 932], ["can", 941], ["correctly", 945], ["identify", 955], ["Sotos", 964], ["syndrome", 970], [".", 978]]}
{"context": "The expression of selenoproteins requires the translational recoding of the UGA stop codon to selenocysteine. In eukaryotes, this requires an RNA stem loop structure in the 3'-untranslated region, termed a selenocysteine insertion sequence (SECIS), and SECIS-binding protein 2 (SBP2). This study implicates SBP2 in dictating the hierarchy of selenoprotein expression, because it is the first to show that SBP2 distinguishes between SECIS elements in vitro. Using RNA electrophoretic mobility shift assays, we demonstrate that a naturally occurring mutation in SBP2, which correlates with abnormal thyroid hormone function in humans, lies within a novel, bipartite RNA-binding domain. This mutation alters the RNA binding affinity of SBP2 such that it no longer stably interacts with a subset of SECIS elements. Assays performed under competitive conditions to mimic intracellular conditions suggest that the differential affinity of SBP2 for various SECIS elements will determine the expression pattern of the selenoproteome. We hypothesize that the selective loss of a subset of selenoproteins, including some involved in thyroid hormone homeostasis, is responsible for the abnormal thyroid hormone metabolism previously observed in the affected individuals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "4a2ea59ce04b469fb5deddf4edb5b587", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[157, 157], [37, 37], [41, 41], [73, 73], [136, 136]], "char_spans": [[950, 954], [241, 245], [253, 257], [432, 436], [795, 799]]}]}], "context_tokens": [["The", 0], ["expression", 4], ["of", 15], ["selenoproteins", 18], ["requires", 33], ["the", 42], ["translational", 46], ["recoding", 60], ["of", 69], ["the", 72], ["UGA", 76], ["stop", 80], ["codon", 85], ["to", 91], ["selenocysteine", 94], [".", 108], ["In", 110], ["eukaryotes", 113], [",", 123], ["this", 125], ["requires", 130], ["an", 139], ["RNA", 142], ["stem", 146], ["loop", 151], ["structure", 156], ["in", 166], ["the", 169], ["3'-untranslated", 173], ["region", 189], [",", 195], ["termed", 197], ["a", 204], ["selenocysteine", 206], ["insertion", 221], ["sequence", 231], ["(", 240], ["SECIS", 241], [")", 246], [",", 247], ["and", 249], ["SECIS", 253], ["-", 258], ["binding", 259], ["protein", 267], ["2", 275], ["(", 277], ["SBP2", 278], [")", 282], [".", 283], ["This", 285], ["study", 290], ["implicates", 296], ["SBP2", 307], ["in", 312], ["dictating", 315], ["the", 325], ["hierarchy", 329], ["of", 339], ["selenoprotein", 342], ["expression", 356], [",", 366], ["because", 368], ["it", 376], ["is", 379], ["the", 382], ["first", 386], ["to", 392], ["show", 395], ["that", 400], ["SBP2", 405], ["distinguishes", 410], ["between", 424], ["SECIS", 432], ["elements", 438], ["in", 447], ["vitro", 450], [".", 455], ["Using", 457], ["RNA", 463], ["electrophoretic", 467], ["mobility", 483], ["shift", 492], ["assays", 498], [",", 504], ["we", 506], ["demonstrate", 509], ["that", 521], ["a", 526], ["naturally", 528], ["occurring", 538], ["mutation", 548], ["in", 557], ["SBP2", 560], [",", 564], ["which", 566], ["correlates", 572], ["with", 583], ["abnormal", 588], ["thyroid", 597], ["hormone", 605], ["function", 613], ["in", 622], ["humans", 625], [",", 631], ["lies", 633], ["within", 638], ["a", 645], ["novel", 647], [",", 652], ["bipartite", 654], ["RNA", 664], ["-", 667], ["binding", 668], ["domain", 676], [".", 682], ["This", 684], ["mutation", 689], ["alters", 698], ["the", 705], ["RNA", 709], ["binding", 713], ["affinity", 721], ["of", 730], ["SBP2", 733], ["such", 738], ["that", 743], ["it", 748], ["no", 751], ["longer", 754], ["stably", 761], ["interacts", 768], ["with", 778], ["a", 783], ["subset", 785], ["of", 792], ["SECIS", 795], ["elements", 801], [".", 809], ["Assays", 811], ["performed", 818], ["under", 828], ["competitive", 834], ["conditions", 846], ["to", 857], ["mimic", 860], ["intracellular", 866], ["conditions", 880], ["suggest", 891], ["that", 899], ["the", 904], ["differential", 908], ["affinity", 921], ["of", 930], ["SBP2", 933], ["for", 938], ["various", 942], ["SECIS", 950], ["elements", 956], ["will", 965], ["determine", 970], ["the", 980], ["expression", 984], ["pattern", 995], ["of", 1003], ["the", 1006], ["selenoproteome", 1010], [".", 1024], ["We", 1026], ["hypothesize", 1029], ["that", 1041], ["the", 1046], ["selective", 1050], ["loss", 1060], ["of", 1065], ["a", 1068], ["subset", 1070], ["of", 1077], ["selenoproteins", 1080], [",", 1094], ["including", 1096], ["some", 1106], ["involved", 1111], ["in", 1120], ["thyroid", 1123], ["hormone", 1131], ["homeostasis", 1139], [",", 1150], ["is", 1152], ["responsible", 1155], ["for", 1167], ["the", 1171], ["abnormal", 1175], ["thyroid", 1184], ["hormone", 1192], ["metabolism", 1200], ["previously", 1211], ["observed", 1222], ["in", 1231], ["the", 1234], ["affected", 1238], ["individuals", 1247], [".", 1258]]}
{"context": "Centrosomes are composed of a centriole pair surrounded by an intricate proteinaceous matrix referred to as pericentriolar material. Although the mechanisms underpinning the control of centriole duplication are now well understood, we know relatively little about the control of centrosome size and shape. Here we used interaction proteomics to identify the E3 ligase HERC2 and the neuralized homologue NEURL4 as novel interaction partners of the centrosomal protein CP110. Using high resolution imaging, we find that HERC2 and NEURL4 localize to the centrosome and that interfering with their function alters centrosome morphology through the appearance of aberrant filamentous structures that stain for a subset of pericentriolar material proteins including pericentrin and CEP135. Using an RNA interference-resistant transgene approach in combination with structure-function analyses, we show that the association between CP110 and HERC2 depends on nonoverlapping regions of NEURL4. Whereas CP110 binding to NEURL4 is dispensable for the regulation of pericentriolar material architecture, its association with HERC2 is required to maintain normal centrosome integrity. NEURL4 is a substrate of HERC2, and together these results indicate that the NEURL4-HERC2 complex participates in the ubiquitin-dependent regulation of centrosome architecture.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edb15e5cd3594668933fa0a9f6c83206", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[173, 173], [86, 86], [41, 41], [200, 200], [94, 94]], "char_spans": [[1151, 1160], [551, 560], [279, 288], [1325, 1334], [610, 619]]}]}], "context_tokens": [["Centrosomes", 0], ["are", 12], ["composed", 16], ["of", 25], ["a", 28], ["centriole", 30], ["pair", 40], ["surrounded", 45], ["by", 56], ["an", 59], ["intricate", 62], ["proteinaceous", 72], ["matrix", 86], ["referred", 93], ["to", 102], ["as", 105], ["pericentriolar", 108], ["material", 123], [".", 131], ["Although", 133], ["the", 142], ["mechanisms", 146], ["underpinning", 157], ["the", 170], ["control", 174], ["of", 182], ["centriole", 185], ["duplication", 195], ["are", 207], ["now", 211], ["well", 215], ["understood", 220], [",", 230], ["we", 232], ["know", 235], ["relatively", 240], ["little", 251], ["about", 258], ["the", 264], ["control", 268], ["of", 276], ["centrosome", 279], ["size", 290], ["and", 295], ["shape", 299], [".", 304], ["Here", 306], ["we", 311], ["used", 314], ["interaction", 319], ["proteomics", 331], ["to", 342], ["identify", 345], ["the", 354], ["E3", 358], ["ligase", 361], ["HERC2", 368], ["and", 374], ["the", 378], ["neuralized", 382], ["homologue", 393], ["NEURL4", 403], ["as", 410], ["novel", 413], ["interaction", 419], ["partners", 431], ["of", 440], ["the", 443], ["centrosomal", 447], ["protein", 459], ["CP110", 467], [".", 472], ["Using", 474], ["high", 480], ["resolution", 485], ["imaging", 496], [",", 503], ["we", 505], ["find", 508], ["that", 513], ["HERC2", 518], ["and", 524], ["NEURL4", 528], ["localize", 535], ["to", 544], ["the", 547], ["centrosome", 551], ["and", 562], ["that", 566], ["interfering", 571], ["with", 583], ["their", 588], ["function", 594], ["alters", 603], ["centrosome", 610], ["morphology", 621], ["through", 632], ["the", 640], ["appearance", 644], ["of", 655], ["aberrant", 658], ["filamentous", 667], ["structures", 679], ["that", 690], ["stain", 695], ["for", 701], ["a", 705], ["subset", 707], ["of", 714], ["pericentriolar", 717], ["material", 732], ["proteins", 741], ["including", 750], ["pericentrin", 760], ["and", 772], ["CEP135", 776], [".", 782], ["Using", 784], ["an", 790], ["RNA", 793], ["interference", 797], ["-", 809], ["resistant", 810], ["transgene", 820], ["approach", 830], ["in", 839], ["combination", 842], ["with", 854], ["structure", 859], ["-", 868], ["function", 869], ["analyses", 878], [",", 886], ["we", 888], ["show", 891], ["that", 896], ["the", 901], ["association", 905], ["between", 917], ["CP110", 925], ["and", 931], ["HERC2", 935], ["depends", 941], ["on", 949], ["nonoverlapping", 952], ["regions", 967], ["of", 975], ["NEURL4", 978], [".", 984], ["Whereas", 986], ["CP110", 994], ["binding", 1000], ["to", 1008], ["NEURL4", 1011], ["is", 1018], ["dispensable", 1021], ["for", 1033], ["the", 1037], ["regulation", 1041], ["of", 1052], ["pericentriolar", 1055], ["material", 1070], ["architecture", 1079], [",", 1091], ["its", 1093], ["association", 1097], ["with", 1109], ["HERC2", 1114], ["is", 1120], ["required", 1123], ["to", 1132], ["maintain", 1135], ["normal", 1144], ["centrosome", 1151], ["integrity", 1162], [".", 1171], ["NEURL4", 1173], ["is", 1180], ["a", 1183], ["substrate", 1185], ["of", 1195], ["HERC2", 1198], [",", 1203], ["and", 1205], ["together", 1209], ["these", 1218], ["results", 1224], ["indicate", 1232], ["that", 1241], ["the", 1246], ["NEURL4-HERC2", 1250], ["complex", 1263], ["participates", 1271], ["in", 1284], ["the", 1287], ["ubiquitin", 1291], ["-", 1300], ["dependent", 1301], ["regulation", 1311], ["of", 1322], ["centrosome", 1325], ["architecture", 1336], [".", 1348]]}
{"context": "The BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22. The majority of CML patients have a breakpoint in the major BCR region of the BCR gene giving rise to e13a2 or e14a2 BCR-ABL transcripts. Occasionally, other BCR breakpoints occur. The current report describes two e6a2 CML patients with imatinib treatment failure and unusual disease progression. One patient was Philadelphia chromosome positive and one was Philadelphia chromosome negative with an atypical BCR-ABL rearrangement, ins (22;9).", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "da064d93bc6d4d6fa5b680d9a08d7890", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[95, 97], [1, 3], [51, 53]], "char_spans": [[559, 565], [4, 10], [268, 274]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["-", 7], ["ABL", 8], ["fusion", 12], ["gene", 19], ["represents", 24], ["the", 35], ["hallmark", 39], ["of", 48], ["chronic", 51], ["myelogenous", 59], ["leukemia", 71], ["(", 80], ["CML", 81], [")", 84], ["and", 86], ["is", 90], ["derived", 93], ["from", 101], ["a", 106], ["translocation", 108], ["between", 122], ["chromosome", 130], ["9", 141], ["and", 143], ["22", 147], [".", 149], ["The", 151], ["majority", 155], ["of", 164], ["CML", 167], ["patients", 171], ["have", 180], ["a", 185], ["breakpoint", 187], ["in", 198], ["the", 201], ["major", 205], ["BCR", 211], ["region", 215], ["of", 222], ["the", 225], ["BCR", 229], ["gene", 233], ["giving", 238], ["rise", 245], ["to", 250], ["e13a2", 253], ["or", 259], ["e14a2", 262], ["BCR", 268], ["-", 271], ["ABL", 272], ["transcripts", 276], [".", 287], ["Occasionally", 289], [",", 301], ["other", 303], ["BCR", 309], ["breakpoints", 313], ["occur", 325], [".", 330], ["The", 332], ["current", 336], ["report", 344], ["describes", 351], ["two", 361], ["e6a2", 365], ["CML", 370], ["patients", 374], ["with", 383], ["imatinib", 388], ["treatment", 397], ["failure", 407], ["and", 415], ["unusual", 419], ["disease", 427], ["progression", 435], [".", 446], ["One", 448], ["patient", 452], ["was", 460], ["Philadelphia", 464], ["chromosome", 477], ["positive", 488], ["and", 497], ["one", 501], ["was", 505], ["Philadelphia", 509], ["chromosome", 522], ["negative", 533], ["with", 542], ["an", 547], ["atypical", 550], ["BCR", 559], ["-", 562], ["ABL", 563], ["rearrangement", 567], [",", 580], ["ins", 582], ["(", 586], ["22;9", 587], [")", 591], [".", 592]]}
{"context": "Parkinson's disease (PD) is a neurodegnerative disorder that is pathologically characterized by the presence of Lewy bodies in the brain. We show that Lewy bodies in PD are strongly immunoreactive for torsinA, the protein product of the DYT1 gene, which is associated with primary generalized dystonia. In the substantia nigra, torsinA immunoreactivity is localized to the periphery of Lewy bodies, whereas, in cortical Lewy bodies it is uniformly distributed. The significance of this finding is unknown, but may implicate torsinA in neuronal dysfunction that occurs in PD as well as in primary dystonia.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "630e6932bb704bc7a85107087e4dd2ea", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegnerative", 30], ["disorder", 47], ["that", 56], ["is", 61], ["pathologically", 64], ["characterized", 79], ["by", 93], ["the", 96], ["presence", 100], ["of", 109], ["Lewy", 112], ["bodies", 117], ["in", 124], ["the", 127], ["brain", 131], [".", 136], ["We", 138], ["show", 141], ["that", 146], ["Lewy", 151], ["bodies", 156], ["in", 163], ["PD", 166], ["are", 169], ["strongly", 173], ["immunoreactive", 182], ["for", 197], ["torsinA", 201], [",", 208], ["the", 210], ["protein", 214], ["product", 222], ["of", 230], ["the", 233], ["DYT1", 237], ["gene", 242], [",", 246], ["which", 248], ["is", 254], ["associated", 257], ["with", 268], ["primary", 273], ["generalized", 281], ["dystonia", 293], [".", 301], ["In", 303], ["the", 306], ["substantia", 310], ["nigra", 321], [",", 326], ["torsinA", 328], ["immunoreactivity", 336], ["is", 353], ["localized", 356], ["to", 366], ["the", 369], ["periphery", 373], ["of", 383], ["Lewy", 386], ["bodies", 391], [",", 397], ["whereas", 399], [",", 406], ["in", 408], ["cortical", 411], ["Lewy", 420], ["bodies", 425], ["it", 432], ["is", 435], ["uniformly", 438], ["distributed", 448], [".", 459], ["The", 461], ["significance", 465], ["of", 478], ["this", 481], ["finding", 486], ["is", 494], ["unknown", 497], [",", 504], ["but", 506], ["may", 510], ["implicate", 514], ["torsinA", 524], ["in", 532], ["neuronal", 535], ["dysfunction", 544], ["that", 556], ["occurs", 561], ["in", 568], ["PD", 571], ["as", 574], ["well", 577], ["as", 582], ["in", 585], ["primary", 588], ["dystonia", 596], [".", 604]]}
{"context": "To study the clinical and molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) infection in children. A total of 37 MRSA strains were isolated from hospitalized patients in Children's Hospital of Fudan University from March 2009 to November 2011. The clinical characteristics were investigated by a cohort study. Furthermore, the mecA, Panton-Valentine leucocidin (PVL) genes were detected by polymerase chain reaction (PCR), and the genotypes of SCCmec were determined by multiplex PCR. (1) Among the 37 MRSA isolates, infections with 21 were acquired from hospital (HA-MRSA), and 16 isolates were acquired from community (CA-MRSA). (2) In the study, MRSA frequently caused respiratory tract infection, and most of the strains were isolated from intensive care unit (ICU). (3) CA-MRSA was most frequently associated with skin and soft tissue infections (SSTI), suppurative tonsillitis, even pneumonia and septicemia. HA-MRSA infection was more aggressive, most frequently associated with pneumonia, septicemia, and central nervous system (CNS) infections, such as meningitis. In children with fever caused by HA-MRSA or CA-MRSA infection, HA-MRSA showed a longer duration of fever, for 10.5 days. C-reactive protein (CRP) level caused by HA-MRSA (63.00 mg/L) was higher than CA-MRSA (9.50 mg/L) , and there were statistically significant differences between the groups (t = 2.5670, P < 0.05). However, there were no statistically significant differences between the groups in white blood cell count (WBC) or procalcitonin (PCT) level. (4) Among 37 MRSA isolates, the whole isolates were mecA gene positive (100%). SCCmec genotyping results showed that the most frequent SCCmec types were type III, 17 isolates, the others including type IV 8 isolates, type II1 isolates, nontypable 11 isolates, type I and type V were not found in this group. Therein, among 21 HA-MRSA isolates, SCCmec III was the most common, 15 isolates, type IV 1 isolates, nontypable 5 isolates; among 16 CA-MRSA isolates, SCCmec type IV was the most common, 7 isolates, type III 2 isolates, type II 1 isolate, nontypable 6 isolates. (5) Among the 37 MRSA isolates, 28 were PVL gene positive; and among 21 HA-MRSA isolates, 17 were PVL gene positive; Among 16 CA-MRSA isolates, 11 were PVL gene positive; There were no statistically significant differences between the groups (\u03c7(2) = 0.735, P > 0.05) . Compared with CA-MRSA, HA-MRSA infection was more aggressive, and induced higher C reactive protein; the dominant epidemic strains of CA-MRSA was SCCmec type IV, and HA-MRSA was SCCmec type III; the positive rate of PVL gene was high.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b4d2ae32fe78473ead5fbb79a9000745", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[461, 461], [531, 531], [108, 108], [121, 121], [263, 263], [131, 131], [251, 251], [387, 387], [507, 507], [222, 222], [14, 14], [447, 447], [321, 321], [511, 511], [218, 218], [474, 474], [24, 24], [227, 227], [413, 413], [540, 540], [183, 183], [158, 158], [95, 95]], "char_spans": [[2208, 2211], [2539, 2542], [598, 601], [654, 657], [1306, 1309], [679, 682], [1269, 1272], [1892, 1895], [2419, 2422], [1151, 1154], [100, 103], [2150, 2153], [1576, 1579], [2428, 2431], [1140, 1143], [2262, 2265], [143, 146], [1170, 1173], [2007, 2010], [2571, 2574], [948, 951], [808, 811], [532, 535]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["clinical", 13], ["and", 22], ["molecular", 26], ["characteristics", 36], ["of", 52], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["infection", 106], ["in", 116], ["children", 119], [".", 127], ["A", 129], ["total", 131], ["of", 137], ["37", 140], ["MRSA", 143], ["strains", 148], ["were", 156], ["isolated", 161], ["from", 170], ["hospitalized", 175], ["patients", 188], ["in", 197], ["Children", 200], ["'s", 208], ["Hospital", 211], ["of", 220], ["Fudan", 223], ["University", 229], ["from", 240], ["March", 245], ["2009", 251], ["to", 256], ["November", 259], ["2011", 268], [".", 272], ["The", 274], ["clinical", 278], ["characteristics", 287], ["were", 303], ["investigated", 308], ["by", 321], ["a", 324], ["cohort", 326], ["study", 333], [".", 338], ["Furthermore", 340], [",", 351], ["the", 353], ["mecA", 357], [",", 361], ["Panton", 363], ["-", 369], ["Valentine", 370], ["leucocidin", 380], ["(", 391], ["PVL", 392], [")", 395], ["genes", 397], ["were", 403], ["detected", 408], ["by", 417], ["polymerase", 420], ["chain", 431], ["reaction", 437], ["(", 446], ["PCR", 447], [")", 450], [",", 451], ["and", 453], ["the", 457], ["genotypes", 461], ["of", 471], ["SCCmec", 474], ["were", 481], ["determined", 486], ["by", 497], ["multiplex", 500], ["PCR", 510], [".", 513], ["(", 515], ["1", 516], [")", 517], ["Among", 519], ["the", 525], ["37", 529], ["MRSA", 532], ["isolates", 537], [",", 545], ["infections", 547], ["with", 558], ["21", 563], ["were", 566], ["acquired", 571], ["from", 580], ["hospital", 585], ["(", 594], ["HA", 595], ["-", 597], ["MRSA", 598], [")", 602], [",", 603], ["and", 605], ["16", 609], ["isolates", 612], ["were", 621], ["acquired", 626], ["from", 635], ["community", 640], ["(", 650], ["CA", 651], ["-", 653], ["MRSA", 654], [")", 658], [".", 659], ["(", 661], ["2", 662], [")", 663], ["In", 665], ["the", 668], ["study", 672], [",", 677], ["MRSA", 679], ["frequently", 684], ["caused", 695], ["respiratory", 702], ["tract", 714], ["infection", 720], [",", 729], ["and", 731], ["most", 735], ["of", 740], ["the", 743], ["strains", 747], ["were", 755], ["isolated", 760], ["from", 769], ["intensive", 774], ["care", 784], ["unit", 789], ["(", 794], ["ICU", 795], [")", 798], [".", 799], ["(", 801], ["3", 802], [")", 803], ["CA", 805], ["-", 807], ["MRSA", 808], ["was", 813], ["most", 817], ["frequently", 822], ["associated", 833], ["with", 844], ["skin", 849], ["and", 854], ["soft", 858], ["tissue", 863], ["infections", 870], ["(", 881], ["SSTI", 882], [")", 886], [",", 887], ["suppurative", 889], ["tonsillitis", 901], [",", 912], ["even", 914], ["pneumonia", 919], ["and", 929], ["septicemia", 933], [".", 943], ["HA", 945], ["-", 947], ["MRSA", 948], ["infection", 953], ["was", 963], ["more", 967], ["aggressive", 972], [",", 982], ["most", 984], ["frequently", 989], ["associated", 1000], ["with", 1011], ["pneumonia", 1016], [",", 1025], ["septicemia", 1027], [",", 1037], ["and", 1039], ["central", 1043], ["nervous", 1051], ["system", 1059], ["(", 1066], ["CNS", 1067], [")", 1070], ["infections", 1072], [",", 1082], ["such", 1084], ["as", 1089], ["meningitis", 1092], [".", 1102], ["In", 1104], ["children", 1107], ["with", 1116], ["fever", 1121], ["caused", 1127], ["by", 1134], ["HA", 1137], ["-", 1139], ["MRSA", 1140], ["or", 1145], ["CA", 1148], ["-", 1150], ["MRSA", 1151], ["infection", 1156], [",", 1165], ["HA", 1167], ["-", 1169], ["MRSA", 1170], ["showed", 1175], ["a", 1182], ["longer", 1184], ["duration", 1191], ["of", 1200], ["fever", 1203], [",", 1208], ["for", 1210], ["10.5", 1214], ["days", 1219], [".", 1223], ["C", 1225], ["-", 1226], ["reactive", 1227], ["protein", 1236], ["(", 1244], ["CRP", 1245], [")", 1248], ["level", 1250], ["caused", 1256], ["by", 1263], ["HA", 1266], ["-", 1268], ["MRSA", 1269], ["(", 1274], ["63.00", 1275], ["mg", 1281], ["/", 1283], ["L", 1284], [")", 1285], ["was", 1287], ["higher", 1291], ["than", 1298], ["CA", 1303], ["-", 1305], ["MRSA", 1306], ["(", 1311], ["9.50", 1312], ["mg", 1317], ["/", 1319], ["L", 1320], [")", 1321], [",", 1323], ["and", 1325], ["there", 1329], ["were", 1335], ["statistically", 1340], ["significant", 1354], ["differences", 1366], ["between", 1378], ["the", 1386], ["groups", 1390], ["(", 1397], ["t", 1398], ["=", 1400], ["2.5670", 1402], [",", 1408], ["P", 1410], ["<", 1412], ["0.05", 1414], [")", 1418], [".", 1419], ["However", 1421], [",", 1428], ["there", 1430], ["were", 1436], ["no", 1441], ["statistically", 1444], ["significant", 1458], ["differences", 1470], ["between", 1482], ["the", 1490], ["groups", 1494], ["in", 1501], ["white", 1504], ["blood", 1510], ["cell", 1516], ["count", 1521], ["(", 1527], ["WBC", 1528], [")", 1531], ["or", 1533], ["procalcitonin", 1536], ["(", 1550], ["PCT", 1551], [")", 1554], ["level", 1556], [".", 1561], ["(", 1563], ["4", 1564], [")", 1565], ["Among", 1567], ["37", 1573], ["MRSA", 1576], ["isolates", 1581], [",", 1589], ["the", 1591], ["whole", 1595], ["isolates", 1601], ["were", 1610], ["mecA", 1615], ["gene", 1620], ["positive", 1625], ["(", 1634], ["100", 1635], ["%", 1638], [")", 1639], [".", 1640], ["SCCmec", 1642], ["genotyping", 1649], ["results", 1660], ["showed", 1668], ["that", 1675], ["the", 1680], ["most", 1684], ["frequent", 1689], ["SCCmec", 1698], ["types", 1705], ["were", 1711], ["type", 1716], ["III", 1721], [",", 1724], ["17", 1726], ["isolates", 1729], [",", 1737], ["the", 1739], ["others", 1743], ["including", 1750], ["type", 1760], ["IV", 1765], ["8", 1768], ["isolates", 1770], [",", 1778], ["type", 1780], ["II1", 1785], ["isolates", 1789], [",", 1797], ["nontypable", 1799], ["11", 1810], ["isolates", 1813], [",", 1821], ["type", 1823], ["I", 1828], ["and", 1830], ["type", 1834], ["V", 1839], ["were", 1841], ["not", 1846], ["found", 1850], ["in", 1856], ["this", 1859], ["group", 1864], [".", 1869], ["Therein", 1871], [",", 1878], ["among", 1880], ["21", 1886], ["HA", 1889], ["-", 1891], ["MRSA", 1892], ["isolates", 1897], [",", 1905], ["SCCmec", 1907], ["III", 1914], ["was", 1918], ["the", 1922], ["most", 1926], ["common", 1931], [",", 1937], ["15", 1939], ["isolates", 1942], [",", 1950], ["type", 1952], ["IV", 1957], ["1", 1960], ["isolates", 1962], [",", 1970], ["nontypable", 1972], ["5", 1983], ["isolates", 1985], [";", 1993], ["among", 1995], ["16", 2001], ["CA", 2004], ["-", 2006], ["MRSA", 2007], ["isolates", 2012], [",", 2020], ["SCCmec", 2022], ["type", 2029], ["IV", 2034], ["was", 2037], ["the", 2041], ["most", 2045], ["common", 2050], [",", 2056], ["7", 2058], ["isolates", 2060], [",", 2068], ["type", 2070], ["III", 2075], ["2", 2079], ["isolates", 2081], [",", 2089], ["type", 2091], ["II", 2096], ["1", 2099], ["isolate", 2101], [",", 2108], ["nontypable", 2110], ["6", 2121], ["isolates", 2123], [".", 2131], ["(", 2133], ["5", 2134], [")", 2135], ["Among", 2137], ["the", 2143], ["37", 2147], ["MRSA", 2150], ["isolates", 2155], [",", 2163], ["28", 2165], ["were", 2168], ["PVL", 2173], ["gene", 2177], ["positive", 2182], [";", 2190], ["and", 2192], ["among", 2196], ["21", 2202], ["HA", 2205], ["-", 2207], ["MRSA", 2208], ["isolates", 2213], [",", 2221], ["17", 2223], ["were", 2226], ["PVL", 2231], ["gene", 2235], ["positive", 2240], [";", 2248], ["Among", 2250], ["16", 2256], ["CA", 2259], ["-", 2261], ["MRSA", 2262], ["isolates", 2267], [",", 2275], ["11", 2277], ["were", 2280], ["PVL", 2285], ["gene", 2289], ["positive", 2294], [";", 2302], ["There", 2304], ["were", 2310], ["no", 2315], ["statistically", 2318], ["significant", 2332], ["differences", 2344], ["between", 2356], ["the", 2364], ["groups", 2368], ["(", 2375], ["\u03c7(2", 2376], [")", 2379], ["=", 2381], ["0.735", 2383], [",", 2388], ["P", 2390], [">", 2392], ["0.05", 2394], [")", 2398], [".", 2400], ["Compared", 2402], ["with", 2411], ["CA", 2416], ["-", 2418], ["MRSA", 2419], [",", 2423], ["HA", 2425], ["-", 2427], ["MRSA", 2428], ["infection", 2433], ["was", 2443], ["more", 2447], ["aggressive", 2452], [",", 2462], ["and", 2464], ["induced", 2468], ["higher", 2476], ["C", 2483], ["reactive", 2485], ["protein", 2494], [";", 2501], ["the", 2503], ["dominant", 2507], ["epidemic", 2516], ["strains", 2525], ["of", 2533], ["CA", 2536], ["-", 2538], ["MRSA", 2539], ["was", 2544], ["SCCmec", 2548], ["type", 2555], ["IV", 2560], [",", 2562], ["and", 2564], ["HA", 2568], ["-", 2570], ["MRSA", 2571], ["was", 2576], ["SCCmec", 2580], ["type", 2587], ["III", 2592], [";", 2595], ["the", 2597], ["positive", 2601], ["rate", 2610], ["of", 2615], ["PVL", 2618], ["gene", 2622], ["was", 2627], ["high", 2631], [".", 2635]]}
{"context": "Infectious mononucleosis is a common, usually self-limited disease. However, infectious mononucleosis may present with severe manifestations. Complications may also occur. Consequently, diagnostic and treatment issues regarding infectious mononucleosis are of major importance. In this review, we focus on the evaluation of articles providing diagnosis and treatment data for infectious mononucleosis, published during the past 2 years. Twelve studies, deriving from extended search in PubMed, were included. Nine studies provided diagnosis data. The evaluated diagnostic methods were real-time PCR (RT-PCR), IgM/IgG antibodies measured with different assays [measurement of Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monospot test]. The sensitivities reported for RT-PCR were high. The available treatment data were scarce (three studies). Two of them suggested that antivirals (mainly acyclovir and valacyclovir) may have a role in the treatment of infectious mononucleosis with complications, whereas the remaining study presented novel potential therapeutic patents including 5-substituted uracyle, azacytosine derivatives, and peptides inhibiting EBV-mediated membrane fusion. RT-PCR and measurement of EBV-VL may provide useful tools for the early diagnosis of infectious mononucleosis in cases with inconclusive serological results. Antiviral agents may provide a useful treatment option in patients with severe infectious mononucleosis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "fba1c150697a4864bbf8aedacd2d8a94", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[113, 116]], "char_spans": [[675, 692]]}]}], "context_tokens": [["Infectious", 0], ["mononucleosis", 11], ["is", 25], ["a", 28], ["common", 30], [",", 36], ["usually", 38], ["self", 46], ["-", 50], ["limited", 51], ["disease", 59], [".", 66], ["However", 68], [",", 75], ["infectious", 77], ["mononucleosis", 88], ["may", 102], ["present", 106], ["with", 114], ["severe", 119], ["manifestations", 126], [".", 140], ["Complications", 142], ["may", 156], ["also", 160], ["occur", 165], [".", 170], ["Consequently", 172], [",", 184], ["diagnostic", 186], ["and", 197], ["treatment", 201], ["issues", 211], ["regarding", 218], ["infectious", 228], ["mononucleosis", 239], ["are", 253], ["of", 257], ["major", 260], ["importance", 266], [".", 276], ["In", 278], ["this", 281], ["review", 286], [",", 292], ["we", 294], ["focus", 297], ["on", 303], ["the", 306], ["evaluation", 310], ["of", 321], ["articles", 324], ["providing", 333], ["diagnosis", 343], ["and", 353], ["treatment", 357], ["data", 367], ["for", 372], ["infectious", 376], ["mononucleosis", 387], [",", 400], ["published", 402], ["during", 412], ["the", 419], ["past", 423], ["2", 428], ["years", 430], [".", 435], ["Twelve", 437], ["studies", 444], [",", 451], ["deriving", 453], ["from", 462], ["extended", 467], ["search", 476], ["in", 483], ["PubMed", 486], [",", 492], ["were", 494], ["included", 499], [".", 507], ["Nine", 509], ["studies", 514], ["provided", 522], ["diagnosis", 531], ["data", 541], [".", 545], ["The", 547], ["evaluated", 551], ["diagnostic", 561], ["methods", 572], ["were", 580], ["real", 585], ["-", 589], ["time", 590], ["PCR", 595], ["(", 599], ["RT", 600], ["-", 602], ["PCR", 603], [")", 606], [",", 607], ["IgM", 609], ["/", 612], ["IgG", 613], ["antibodies", 617], ["measured", 628], ["with", 637], ["different", 642], ["assays", 652], ["[", 659], ["measurement", 660], ["of", 672], ["Epstein", 675], ["-", 682], ["Barr", 683], ["virus", 688], ["viral", 694], ["load", 700], ["(", 705], ["EBV", 706], ["-", 709], ["VL", 710], [")", 712], ["in", 714], ["peripheral", 717], ["blood", 728], [",", 733], ["neutrophil", 735], ["/", 745], ["lymphocyte", 746], ["/", 756], ["monocyte", 757], ["counts", 766], [",", 772], ["C", 774], ["-", 775], ["reactive", 776], ["protein", 785], ["values", 793], [",", 799], ["and", 801], ["monospot", 805], ["test].", 814], ["The", 821], ["sensitivities", 825], ["reported", 839], ["for", 848], ["RT", 852], ["-", 854], ["PCR", 855], ["were", 859], ["high", 864], [".", 868], ["The", 870], ["available", 874], ["treatment", 884], ["data", 894], ["were", 899], ["scarce", 904], ["(", 911], ["three", 912], ["studies", 918], [")", 925], [".", 926], ["Two", 928], ["of", 932], ["them", 935], ["suggested", 940], ["that", 950], ["antivirals", 955], ["(", 966], ["mainly", 967], ["acyclovir", 974], ["and", 984], ["valacyclovir", 988], [")", 1000], ["may", 1002], ["have", 1006], ["a", 1011], ["role", 1013], ["in", 1018], ["the", 1021], ["treatment", 1025], ["of", 1035], ["infectious", 1038], ["mononucleosis", 1049], ["with", 1063], ["complications", 1068], [",", 1081], ["whereas", 1083], ["the", 1091], ["remaining", 1095], ["study", 1105], ["presented", 1111], ["novel", 1121], ["potential", 1127], ["therapeutic", 1137], ["patents", 1149], ["including", 1157], ["5-substituted", 1167], ["uracyle", 1181], [",", 1188], ["azacytosine", 1190], ["derivatives", 1202], [",", 1213], ["and", 1215], ["peptides", 1219], ["inhibiting", 1228], ["EBV", 1239], ["-", 1242], ["mediated", 1243], ["membrane", 1252], ["fusion", 1261], [".", 1267], ["RT", 1269], ["-", 1271], ["PCR", 1272], ["and", 1276], ["measurement", 1280], ["of", 1292], ["EBV", 1295], ["-", 1298], ["VL", 1299], ["may", 1302], ["provide", 1306], ["useful", 1314], ["tools", 1321], ["for", 1327], ["the", 1331], ["early", 1335], ["diagnosis", 1341], ["of", 1351], ["infectious", 1354], ["mononucleosis", 1365], ["in", 1379], ["cases", 1382], ["with", 1388], ["inconclusive", 1393], ["serological", 1406], ["results", 1418], [".", 1425], ["Antiviral", 1427], ["agents", 1437], ["may", 1444], ["provide", 1448], ["a", 1456], ["useful", 1458], ["treatment", 1465], ["option", 1475], ["in", 1482], ["patients", 1485], ["with", 1494], ["severe", 1499], ["infectious", 1506], ["mononucleosis", 1517], [".", 1530]]}
{"context": "Deubiquitinating enzymes (DUbs) play important roles in many ubiquitin-dependent pathways, yet how DUbs themselves are regulated is not well understood. Here, we provide insight into the mechanism by which ubiquitination directly enhances the activity of ataxin-3, a DUb implicated in protein quality control and the disease protein in the polyglutamine neurodegenerative disorder, Spinocerebellar Ataxia Type 3. We identify Lys-117, which resides near the catalytic triad, as the primary site of ubiquitination in wild type and pathogenic ataxin-3. Further studies indicate that ubiquitin-dependent activation of ataxin-3 at Lys-117 is important for its ability to reduce high molecular weight ubiquitinated species in cells. Ubiquitination at Lys-117 also facilitates the ability of ataxin-3 to induce aggresome formation in cells. Finally, structure-function studies support a model of activation whereby ubiquitination at Lys-117 enhances ataxin-3 activity independent of the known ubiquitin-binding sites in ataxin-3, most likely through a direct conformational change in or near the catalytic domain.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "76df6ea078eb43ef838474f8a30b5d15", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[160, 160], [149, 149], [99, 99], [125, 125], [42, 42], [88, 88]], "char_spans": [[1013, 1020], [943, 950], [614, 621], [785, 792], [255, 262], [540, 547]]}]}], "context_tokens": [["Deubiquitinating", 0], ["enzymes", 17], ["(", 25], ["DUbs", 26], [")", 30], ["play", 32], ["important", 37], ["roles", 47], ["in", 53], ["many", 56], ["ubiquitin", 61], ["-", 70], ["dependent", 71], ["pathways", 81], [",", 89], ["yet", 91], ["how", 95], ["DUbs", 99], ["themselves", 104], ["are", 115], ["regulated", 119], ["is", 129], ["not", 132], ["well", 136], ["understood", 141], [".", 151], ["Here", 153], [",", 157], ["we", 159], ["provide", 162], ["insight", 170], ["into", 178], ["the", 183], ["mechanism", 187], ["by", 197], ["which", 200], ["ubiquitination", 206], ["directly", 221], ["enhances", 230], ["the", 239], ["activity", 243], ["of", 252], ["ataxin-3", 255], [",", 263], ["a", 265], ["DUb", 267], ["implicated", 271], ["in", 282], ["protein", 285], ["quality", 293], ["control", 301], ["and", 309], ["the", 313], ["disease", 317], ["protein", 325], ["in", 333], ["the", 336], ["polyglutamine", 340], ["neurodegenerative", 354], ["disorder", 372], [",", 380], ["Spinocerebellar", 382], ["Ataxia", 398], ["Type", 405], ["3", 410], [".", 411], ["We", 413], ["identify", 416], ["Lys-117", 425], [",", 432], ["which", 434], ["resides", 440], ["near", 448], ["the", 453], ["catalytic", 457], ["triad", 467], [",", 472], ["as", 474], ["the", 477], ["primary", 481], ["site", 489], ["of", 494], ["ubiquitination", 497], ["in", 512], ["wild", 515], ["type", 520], ["and", 525], ["pathogenic", 529], ["ataxin-3", 540], [".", 548], ["Further", 550], ["studies", 558], ["indicate", 566], ["that", 575], ["ubiquitin", 580], ["-", 589], ["dependent", 590], ["activation", 600], ["of", 611], ["ataxin-3", 614], ["at", 623], ["Lys-117", 626], ["is", 634], ["important", 637], ["for", 647], ["its", 651], ["ability", 655], ["to", 663], ["reduce", 666], ["high", 673], ["molecular", 678], ["weight", 688], ["ubiquitinated", 695], ["species", 709], ["in", 717], ["cells", 720], [".", 725], ["Ubiquitination", 727], ["at", 742], ["Lys-117", 745], ["also", 753], ["facilitates", 758], ["the", 770], ["ability", 774], ["of", 782], ["ataxin-3", 785], ["to", 794], ["induce", 797], ["aggresome", 804], ["formation", 814], ["in", 824], ["cells", 827], [".", 832], ["Finally", 834], [",", 841], ["structure", 843], ["-", 852], ["function", 853], ["studies", 862], ["support", 870], ["a", 878], ["model", 880], ["of", 886], ["activation", 889], ["whereby", 900], ["ubiquitination", 908], ["at", 923], ["Lys-117", 926], ["enhances", 934], ["ataxin-3", 943], ["activity", 952], ["independent", 961], ["of", 973], ["the", 976], ["known", 980], ["ubiquitin", 986], ["-", 995], ["binding", 996], ["sites", 1004], ["in", 1010], ["ataxin-3", 1013], [",", 1021], ["most", 1023], ["likely", 1028], ["through", 1035], ["a", 1043], ["direct", 1045], ["conformational", 1052], ["change", 1067], ["in", 1074], ["or", 1077], ["near", 1080], ["the", 1085], ["catalytic", 1089], ["domain", 1099], [".", 1105]]}
{"context": "Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE \u03b52, ApoE \u03b53 and ApoE \u03b54 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE \u03b54 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the \u03b54 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n=68) of heterozygous \u03b53\u03b54 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n=669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2594b3b5c34d4b7f830baf5eb3094b4c", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[286, 287]], "char_spans": [[1598, 1610]]}]}], "context_tokens": [["Allelic", 0], ["polymorphism", 8], ["of", 21], ["the", 24], ["apolipoprotein", 28], ["E", 43], ["(", 45], ["ApoE", 46], [")", 50], ["gene", 52], ["(", 57], ["ApoE", 58], ["\u03b52", 63], [",", 65], ["ApoE", 67], ["\u03b53", 72], ["and", 75], ["ApoE", 79], ["\u03b54", 84], ["alleles", 87], [")", 94], ["gives", 96], ["rise", 102], ["to", 107], ["three", 110], ["protein", 116], ["isoforms", 124], ["(", 133], ["ApoE2", 134], [",", 139], ["ApoE3", 141], ["and", 147], ["ApoE4", 151], [")", 156], ["that", 158], ["differ", 163], ["by", 170], ["1", 173], ["or", 175], ["2", 178], ["amino", 180], ["acids", 186], [".", 191], ["Inheritance", 193], ["of", 205], ["the", 208], ["ApoE", 212], ["\u03b54", 217], ["allele", 220], ["is", 227], ["a", 230], ["risk", 232], ["factor", 237], ["for", 244], ["developing", 248], ["Alzheimer", 259], ["'s", 268], ["disease", 271], ["(", 279], ["AD", 280], [")", 282], [".", 283], ["The", 285], ["potential", 289], ["diagnostic", 299], ["value", 310], ["of", 316], ["ApoE", 319], ["protein", 324], ["levels", 332], ["in", 339], ["biological", 342], ["fluids", 353], ["(", 360], ["i.e.", 361], ["cerebrospinal", 366], ["fluid", 380], [",", 385], ["plasma", 387], ["and", 394], ["serum", 398], [")", 403], ["for", 405], ["distinguishing", 409], ["between", 424], ["AD", 432], ["patients", 435], ["and", 444], ["healthy", 448], ["elderly", 456], ["subjects", 464], ["is", 473], ["subject", 476], ["to", 484], ["great", 487], ["controversy", 493], [".", 504], ["Although", 506], ["a", 515], ["recent", 517], ["study", 524], ["reported", 530], ["subnormal", 539], ["total", 549], ["ApoE", 555], ["and", 560], ["ApoE4", 564], ["levels", 570], ["in", 577], ["the", 580], ["plasma", 584], ["of", 591], ["AD", 594], ["patients", 597], [",", 605], ["other", 607], ["studies", 613], ["have", 621], ["found", 626], ["normal", 632], ["or", 639], ["even", 642], ["elevated", 647], ["protein", 656], ["levels", 664], ["(", 671], ["versus", 672], ["controls", 679], [")", 687], [".", 688], ["Because", 690], ["all", 698], ["previously", 702], ["reported", 713], ["assays", 722], ["were", 729], ["based", 734], ["on", 740], ["immunoenzymatic", 743], ["techniques", 759], [",", 769], ["we", 771], ["decided", 774], ["to", 782], ["develop", 785], ["an", 793], ["orthogonal", 796], ["assay", 807], ["based", 813], ["on", 819], ["targeted", 822], ["mass", 831], ["spectrometry", 836], ["by", 849], ["tracking", 852], ["(", 861], ["i", 862], [")", 863], ["a", 865], ["proteotypic", 867], ["peptide", 879], ["common", 887], ["to", 894], ["all", 897], ["ApoE", 901], ["isoforms", 906], ["and", 915], ["(", 919], ["ii", 920], [")", 922], ["a", 924], ["peptide", 926], ["that", 934], ["is", 939], ["specific", 942], ["for", 951], ["the", 955], ["\u03b54", 959], ["allele", 962], [".", 968], ["After", 970], ["trypsin", 976], ["digestion", 984], [",", 993], ["the", 995], ["ApoE4-specific", 999], ["peptide", 1014], ["contains", 1022], ["an", 1031], ["oxidation", 1034], ["-", 1043], ["prone", 1044], ["methionine", 1050], ["residue", 1061], [".", 1068], ["The", 1070], ["endogenous", 1074], ["methionine", 1085], ["oxidation", 1096], ["level", 1106], ["was", 1112], ["evaluated", 1116], ["in", 1126], ["a", 1129], ["small", 1131], ["cohort", 1137], ["(", 1144], ["n=68", 1145], [")", 1149], ["of", 1151], ["heterozygous", 1154], ["\u03b53\u03b54", 1167], ["carriers", 1172], ["containing", 1181], ["both", 1192], ["healthy", 1197], ["controls", 1205], ["and", 1214], ["AD", 1218], ["patients", 1221], [".", 1229], ["As", 1231], ["expected", 1234], [",", 1242], ["the", 1244], ["proportion", 1248], ["of", 1259], ["oxidized", 1262], ["residues", 1271], ["varied", 1280], ["from", 1287], ["0", 1292], ["to", 1294], ["10", 1297], ["%", 1299], [",", 1300], ["with", 1302], ["an", 1307], ["average", 1310], ["of", 1318], ["5", 1321], ["%", 1322], [".", 1323], ["We", 1325], ["therefore", 1328], ["developed", 1338], ["a", 1348], ["standardized", 1350], ["strategy", 1363], ["for", 1372], ["the", 1376], ["unbiased", 1380], [",", 1388], ["absolute", 1390], ["quantification", 1399], ["of", 1414], ["ApoE4", 1417], [",", 1422], ["based", 1424], ["on", 1430], ["performic", 1433], ["acid", 1443], ["oxidization", 1448], ["of", 1460], ["methionine", 1463], [".", 1473], ["Once", 1475], ["the", 1480], ["sample", 1484], ["workflow", 1491], ["had", 1500], ["been", 1504], ["thoroughly", 1509], ["validated", 1520], [",", 1529], ["it", 1531], ["was", 1534], ["applied", 1538], ["to", 1546], ["the", 1549], ["concomitant", 1553], ["quantification", 1565], ["of", 1580], ["total", 1583], ["ApoE", 1589], ["and", 1594], ["ApoE4", 1598], ["isoform", 1604], ["in", 1612], ["a", 1615], ["large", 1617], ["case", 1623], ["-", 1627], ["control", 1628], ["study", 1636], ["(", 1642], ["n=669", 1643], [")", 1648], [".", 1649], ["The", 1651], ["final", 1655], ["measurements", 1661], ["were", 1674], ["consistent", 1679], ["with", 1690], ["most", 1695], ["previously", 1700], ["reported", 1711], ["ApoE", 1720], ["concentration", 1725], ["values", 1739], ["and", 1746], ["confirm", 1750], ["the", 1758], ["influence", 1762], ["of", 1772], ["the", 1775], ["different", 1779], ["alleles", 1789], ["on", 1797], ["the", 1800], ["protein", 1804], ["expression", 1812], ["level", 1823], [".", 1828], ["Our", 1830], ["results", 1834], ["illustrate", 1842], ["(", 1853], ["i", 1854], [")", 1855], ["the", 1857], ["reliability", 1861], ["of", 1873], ["selected", 1876], ["reaction", 1885], ["monitoring", 1894], ["-", 1904], ["based", 1905], ["assays", 1911], ["and", 1918], ["(", 1922], ["ii", 1923], [")", 1925], ["the", 1927], ["value", 1931], ["of", 1937], ["the", 1940], ["oxidization", 1944], ["step", 1956], ["for", 1961], ["unbiased", 1965], ["monitoring", 1974], ["of", 1985], ["methionine", 1988], ["-", 1998], ["containing", 1999], ["proteotypic", 2010], ["peptides", 2022], [".", 2030], ["Furthermore", 2032], [",", 2043], ["a", 2045], ["statistical", 2047], ["analysis", 2059], ["indicated", 2068], ["that", 2078], ["neither", 2083], ["total", 2091], ["ApoE", 2097], ["and", 2102], ["ApoE4", 2106], ["levels", 2112], ["nor", 2119], ["the", 2123], ["ApoE", 2127], ["/", 2131], ["ApoE4", 2132], ["ratio", 2138], ["correlated", 2144], ["with", 2155], ["the", 2160], ["diagnosis", 2164], ["of", 2174], ["AD", 2177], [".", 2179], ["These", 2181], ["findings", 2187], ["reinforce", 2196], ["the", 2206], ["conclusions", 2210], ["of", 2222], ["previous", 2225], ["studies", 2234], ["in", 2242], ["which", 2245], ["plasma", 2251], ["ApoE", 2258], ["levels", 2263], ["had", 2270], ["no", 2274], ["obvious", 2277], ["clinical", 2285], ["significance", 2294], [".", 2306]]}
{"context": "A 75-year-old woman presented with altered mental status, septic picture, and influenza-like symptoms. Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result. Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection. Herein, we report the first case of a heterophile-positive mononucleosis syndrome caused by acute CMV infection in an elderly immunocompetent woman. This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "0460fc84d839453e88d73ec2691da940", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[54, 57], [43, 46]], "char_spans": [[324, 341], [271, 288]]}]}], "context_tokens": [["A", 0], ["75-year", 2], ["-", 9], ["old", 10], ["woman", 14], ["presented", 20], ["with", 30], ["altered", 35], ["mental", 43], ["status", 50], [",", 56], ["septic", 58], ["picture", 65], [",", 72], ["and", 74], ["influenza", 78], ["-", 87], ["like", 88], ["symptoms", 93], [".", 101], ["Initial", 103], ["investigations", 111], ["revealed", 126], ["atypical", 135], ["lymphocytosis", 144], [",", 157], ["thrombocytopenia", 159], [",", 175], ["elevated", 177], ["liver", 186], ["enzymes", 192], [",", 199], ["and", 201], ["a", 205], ["positive", 207], ["monospot", 216], ["test", 225], ["result", 230], [".", 236], ["Further", 238], ["investigation", 246], ["showed", 260], ["the", 267], ["Epstein", 271], ["-", 278], ["Barr", 279], ["virus", 284], ["viral", 290], ["capsid", 296], ["antibody", 303], ["IgM", 312], ["/", 315], ["IgG", 316], ["and", 320], ["Epstein", 324], ["-", 331], ["Barr", 332], ["virus", 337], ["DNA", 343], ["by", 347], ["polymerase", 350], ["chain", 361], ["reaction", 367], ["to", 376], ["be", 379], ["negative", 382], [";", 390], ["however", 392], [",", 399], ["interestingly", 401], ["her", 415], ["cytomegalovirus", 419], ["(", 435], ["CMV", 436], [")", 439], ["IgM", 441], ["and", 445], ["IgG", 449], ["were", 453], ["positive", 458], [",", 466], ["suggesting", 468], ["that", 479], ["her", 484], ["mononucleosis", 488], ["-", 501], ["like", 502], ["syndrome", 507], ["was", 516], ["due", 520], ["to", 524], ["acute", 527], ["CMV", 533], ["infection", 537], [".", 546], ["Herein", 548], [",", 554], ["we", 556], ["report", 559], ["the", 566], ["first", 570], ["case", 576], ["of", 581], ["a", 584], ["heterophile", 586], ["-", 597], ["positive", 598], ["mononucleosis", 607], ["syndrome", 621], ["caused", 630], ["by", 637], ["acute", 640], ["CMV", 646], ["infection", 650], ["in", 660], ["an", 663], ["elderly", 666], ["immunocompetent", 674], ["woman", 690], [".", 695], ["This", 697], ["case", 702], ["conveys", 707], ["that", 715], ["monospot", 720], ["test", 729], ["can", 734], ["yield", 738], ["false", 744], ["-", 749], ["positive", 750], ["result", 759], ["in", 766], ["the", 769], ["setting", 773], ["of", 781], ["acute", 784], ["CMV", 790], ["infection", 794], [".", 803]]}
